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1. Abstract/Zusammenfassung 
1.1. Abstract 
Hepatocellular carcinoma (HCC) is amongst the most frequent human cancers and 
its cure is difficult since resection mostly is not possible. Although there are attempts 
for systemic therapies, the variety and differences in the underlying genetic 
alterations and disruptions of signalling pathways makes this a difficult goal to 
achieve. One well-known oncogenic transcription factor involved in the development 
of HCC, is Stat3, whose targets drive proliferation and angiogenesis and counteract 
apoptosis. In addition to these tumor-promoting functions Stat3 was found to act 
tumor-suppressive under certain circumstances. However, this conversion from pro- 
to anti-oncogenic Stat3 actions is mechanistically poorly understood. We previously 
found Stat3 to act tumor suppressive in the absence of p14ARF, a tumor suppressor 
frequently lost in HCC. Since Janus kinases (Jaks) are the canonical activators of 
Stat3 we addressed the question wheter the absence of p14ARF affects their 
activation, and which of them induces Stat3.activation First, we found that de novo 
RNA and protein synthesis is necessary for Stat3 activation irrespective of p14ARF 
expression. Further, we identified Jak1 as the crucial kinase for IL-6 induced Stat3 
phosphorylation. Jak1 was required for Stat3 activation independent of p14ARF 
expression. Since we found that phosphorylation of Stat3 was circumvented in 
p14ARF-negative experimental HCC, we assumed that Jak1 activity is blocked by an 
unknown mechanism. From these data we propose that p14ARF binds to a nuclear 
protein that can also interact with unphosphorylated-Stat3 (U-Stat3). This interaction 
is assumed to prevent U-Stat3 from modulating transcription and thus the absence 
absence of  p14ARF changes the subset of Stat3-modulated genes.  
We further observed that Stat3 was required to exert TGF-β1 induced anti-
proliferative effects in hepatoma cells. Thus, the question arose, wheter Stat3 is 
required for the canonical TGF-β/Smad signalling. We observed that TGF-β1-induced 
translocation of Smads to the nuclues was not affected by the lack of Stat3, but the 
overall Smad level was reduced. Thus we propose that Stat3 is crucial for TGF-β1 
functions on a transcriptional level.  
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1.2. Zusammenfassung 
Das Leberzellkarzinom (HCC) gehört zu den am häufigsten vorkommenden 
Krebserkrankungen. Therapie und Heilung sind schwierig, da eine operative 
Entfernung meist nicht möglich ist. Es gibt zahlreiche Bemühungen effektive 
systemische Therapien zu entwickeln, was sich aber aufgrund der Heterogenität der 
zugrundeliegenden genetischen Veränderungen und Störungen der 
Signaltransduktion als schwierig erweist.  
Stat3 ist ein Transkriptionsfaktor der in den meisten HCC Fällen erhöhte Aktivität 
aufweist. Seine Zielgene fördern Proliferation und Angiogenese und wirken der 
Apoptose entgegen. Unter bestimmten Bedingungen kann Stat3 aber auch tumor-
suppressiv wirken. Die zugrundeliegenden Mechanismen für diese Wandlung sind 
jedoch weitgehend unbekannt. Unsere rezenten Untersuchungen haben gezeigt, 
dass Stat3 in Abwesenheit von p14ARF als Tumorsuppressor fungiert. p14ARF ist ein 
Tumorsuppressor der in HCC häufig deaktiviert ist. Da Janus Kinasen (Jaks) für die 
Stat3-Aktivierung verantwortlich sind, wollten wir wissen, ob die Abwesenheit von 
p14ARF Einfluss auf ihre Aktivität und die Stat3-Phosphorylierung nimmt. Es zeigte 
sich, dass unabhängig vom p14ARF-Status die de novo RNA-. und Proteinsynthese 
für die Stat3-Phosphorylierung notwendig ist. Weiters fanden wir heraus, dass Jak1 
für die IL-6-induzierte Stat3-Aktivierung verantwortlich ist, und dass p14ARF auf die 
Aktivität von Jak1 keinen Einfluss hat. Da sich zuvor gezeigt hatte, dass in p14ARF-
negativen experimentellen HCC die Phosphorylierung von Jak1 verhindert wird, 
schließen wir, dass dies durch einen anderen Modulator geschieht und p14ARF selbst 
weiter downstream agiert. Unsere These ist, dass p14ARF im Nukleus an einen Faktor 
bindet und diesen inhibiert, der auch an unphosphoryliertes Stat3 bindet, wodurch 
ein anderes Set an Genen transkriptionell moduliert wird.  
Weiters konnten wir beobachten, dass Stat3 für die TGF-β1-induzierten anti-
proliferativen Effekten nötig ist. Daher stellte sich die Frage, ob Stat3 für die 
Aktivierung von Smads und deren Translokation in den Nukleus verantwortlich ist. 
Dies war nicht der Fall. Da wir jedoch reduzierte Mengen von Smads fanden, gehen 
wir davon aus, dass Stat3 auf transkriptioneller Ebene die Ausführung TGF-β1-
induzierter Effekte moduliert. 
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2. Introduction 
2.1. Malignant transformation 
To develop cancer multiple mutations and/or disruptions of signalling pathways and 
control mechansism are necessary (1). There are a few characteristics typical for 
cancer cells. The most prominent and crucially important one is the loss of growth 
and proliferation control resulting in unlimited growth (1). Insensitivity to growth 
limiting or apoptotic signals and independence of growth promoting signals contribute 
to this feature. The tumor microenvironment and particular cells of the immune 
system lead to a tumor-promoting inflammatory environment rather than tumor 
surveillance (1). Furthermore, influencing its environment in a way to induce 
neovascularisation is a means of the tumor to ensure its supply and thus, survival 
and further growth (Fig. 1) (1). A late step in tumorigenesis is metastasis, thus the 
ability to detach from the original tumor cell assembly and invade other tissues (1).  
 
 
 
Figure 1: Typical features of cancer cells (1). 
 
2.2 Hepatocellular carcinoma  
Hepatocellular carcinoma (HCC) is the fifth most common cancer among solid tumors 
worldwide and the third leading cause of cancer-related mortality with 500.000 deaths 
annually (2). It is a complex disease, which develops over years and is clinically 
diagnosed often only at late stages (3). The development is a multistep process with 
accumulation of aberrant genetic and epigenetic changes (Fig. 2) (3, 4). Common 
risk factors are infection with hepatitis B or C virus, alcohol abuse and fatty liver 
disease, where progression of disease is associated with fibrosis and cirrhosis in 
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most cases (3-5). Aflatoxin intoxication and genetic disorders like tyrosinosis 
contribute to development of HCC without concomitant fibrosis or cirrhosis (3). HCV, 
HBV, Aflotoxin together are responsible for 80 % of HCC development in humans (5).  
 
 
 
Figure 2: Triggers for HCC and molecular changes during progression (3).  
 
There are some typically affected genes and regulatory circuits, however, the pattern 
of disruptions and changes is very heterogenous among the individual HCCs (4, 5). 
Typical alterations are mutations, allelic deletions and epigenetic changes like 
abnormal promoter methylation, leading to activation of oncogenes and inactivation 
of tumor suppressors (4, 5). Besides this, the accelerated proliferation of hepatocytes 
and selective growth of monoclonal cell populations are typical already in 
preneoplastic phases, and are even enhanced in HCC (5). The accumulation of 
genetic changes and the increasing genetic instability is accompanied by 
characteristic alterations of liver tissue and affected hepatocytes (Fig. 3) (5). Fibrosis 
and inflammation play key roles in this development, since they trigger changes of 
the matrix and the microenvironment (5). During these processes many hepatocytes 
die and thus, inflammatory cells infiltrate the liver and connective tissue is deposited 
(5). In the course of further progression foci of phenotypically altered hepatocytes 
develop into dysplastic nodules finally resulting in full blown HCC (5). Inflammation is 
considered to participate in the development and progression of many tumors, but is 
especially important in the course of hepatocarcinogenesis, since fibrotic and cirrhotic 
stages most frequently precede HCC (6). Overexpression of inflammatory cytokines 
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and aberrant inflammatory responses can enhance the proliferation of malignant cells 
and contribute to generating a tumor-promoting environment (6-8). 
 
 
Figure 3: Changes of hepatocytes in the typical time course of HCC (5). 
 
Structural aberrations occur only in a few genes and slowly during early stages, but 
are increased in dysplastic hepatocytes and HCC (5). Alleleic deletions were found in 
30-50 % of patients suffering from chronic hepatitis or cirrhosis, while 70−80% of 
dysplastic nodules and almost all investigated HCC livers showed this alteration (5, 
9-11). Some chromosomal regions are especially prone to allelic deletion, loss or 
gain of chromosomal regions. Within these often affected regions lie the tumor-
suppressor genes p53, Rb, and CDKN2A which are often inactivated by deletion or 
mutation, while the oncogene c-myc is frequently overexpressed and was found to be 
amplified in 30% of HCCs (4, 5, 11). Upon impaired control and repair mechanisms it 
is likely that structural aberrations accumulate during accelerated proliferation (4, 5). 
Although aberrant promoter methylation is a frequent and early event in 
hepatocarcinogenesis, changes in expression levels precede epigenetic alterations 
(4, 5). Expression of cytokines such as transforming growth factor α (TGF-α) and 
growth factors like insulin-like growth factor II (IGF-II) is induced by cytokines 
secreted by inflammatory cells or viruses, or in response to cell death and results in 
enhanced proliferation of hepatocytes and thus, development of monoclonal cell 
populations (5). Still, hypermethylation of CpG islands is already found in hepatic 
cirrhosis (4, 5). Epigenetic alterations increase in the progression from pre-
malignancy to HCC, in which hypo- or hypermethylation of promoters is a frequent 
and common condition (4, 5). Accordingly, the expression of DNA-methyltransferases 
(DNMT-1, DNMT-3) is enhanced in chronic hepatitis and cirrhosis, and strongly 
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increased in HCC (5, 12). Interestingly, especially in cirrhotic, HBV- or HCV-
associated HCC the methylation frequency was found to be enhanced compared to 
other HCCs (4). Methylation in HCC affects genes involved in apoptosis, cell 
adhesion, DNA repair, mismatch repair, inhibition of several proteins like cell cycle 
regulators such as cyclin-dependent kinases (CDK), cell cycle regulators p16Ink4a, 
p14ARF, MDM2, metalloproteases (MMP) or cytokines and regulators of signal 
transduction like SOCS (5). Still, early epigenetic changes and structural aberrations 
are not sufficient to induce malignant phenotypes in hepatocytes, although some 
epigenetic changes act indirect and generate conditions for development of cell 
populations with structurally and functionally abberant genes (5). Some epigenetic 
changes also directly precede structural aberrations, like in the cases of c-myc and 
CDKN2A (5). The overexpression of c-myc is associated with promoter 
hypomethylation in early stages and with following gene amplification later on (5). 
 
2.3. Altered signal transduction in HCC 
As every type of cancer, hepatocarcinogenesis shows positive or negative changes 
in various signalling pathways and regulatory circuits (1, 5, 13). They can get 
disrupted or hyperactivated by different mechanisms (1, 5, 13). These intracellular 
signalling networks are complex, often redundant and crucial for many cellular 
processes like maintenance of cell number homeostasis, growth and proliferation 
control, the decision between survival or apoptosis, and motility (Fig. 4) (1, 5, 14). 
Since there are multiple crosstalks and interconnecting nodes between them, the 
disruption of one gene or the aberrant activity of one protein can affect several 
events and have severe consequences (5).  
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Figure 4: Signalling circuits contributing to tumorigenesis (1). 
 
While strictly controlled in normal cells, tumor cells frequently show aberrations in 
signalling cascades, either being disrupted or overactivated, but mostly resulting in 
elevated proliferation (1, 13).  Growth factor and cytokine levels can be enhanced 
due to elevated secretion by the tumor cell itself or by cells of the surrounding 
microenvironment, which got triggered to do so by the tumor cells (1, 6). Further 
enhanced expression or mutations in receptors can lead to hyperresponsibility (1). 
Mutations in receptors which entail ligand-independent signalling or mutations 
constitutively activating downstream components render the cell independent of 
growth promoting signals (1). Importantly, also the disruption of negative feed-back 
loops can be responsible for sustained and thus over-active signalling (1). Also in 
HCC, mutations, deregulated expression or uncontrolled activity of growth factors 
and cytokines, their receptor tyrosine kinases or intracellular tyrosine kinases further 
downstream in the signalling cascade are involved in malignant progression, namely 
survival, proliferation, angiogenesis, inflammation and invasion (5, 14-16).  
Due to underlying liver diseases, resection is suitable only for few HCC patients and 
was shown to be effective only at early stages (13, 17). Thus, more than 80% of 
patients suffer from inoperable HCC with very poor prognosis (13). Even if resection 
is possible, there is a very high recurrence rate of over 60% due to metastasis or new 
development (13, 17). Furthermore, HCC is highly resistant to available systemic 
therapies (13, 17).  Since there is no effective first-line treatment for advanced HCC, 
research is focussed on the development of novel targeted therapies (13, 17).  
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Recent findings proved aberrant proliferative signalling pathways, including 
Raf/MEK/ERK, PI-3K/Akt/mTOR, and Jak/Stat pathways accountable for tumor 
initiation and progression, and thus, signal transduction and tyrosine kinases became 
putative targets for intervention (13, 17).   
 
2.4. Receptor tyrosine kinases (RTK) in HCC 
Receptor tyrosine kinases are crucially involved in the control of survival, 
proliferation, angiogenesis, inflammation and invasion (7, 13).  Epidermal growth 
factor receptor (EGFR) is expressed in a high proportion of HCCs and the 
proliferation of HCC cells was found to depend on stimulation of EGFR by TGF-α or 
EGF (13, 18).  Hepatocyte growth factor (HGF) and its receptor c-Met have been 
implicated in HCC playing a role in growth, survival and invasion (13). Point 
mutations in MET have been detected and elevated HGF levels have been identified 
as potential predictor of poor prognosis (13). Vascular endothelial growth factor 
(VEGF), Platelet-derived growth factor (PDGF) and basic FGF (bFGF; FGF-2) are 
three important pro-angiogenic factors and thus, play important roles in 
neovascularization, invasiveness, and the metastatic potential of HCC (13). 
Activation of the VEGF-receptor family, particularly activation of VEGFR-2 by VEGF 
plays a primary role in tumor angiogenesis and accordingly, elevated levels of VEGF 
are associated with postoperative recurrence and poor prognosis (13). VEGF 
expression is detected in dysplastic nodules, and increases during the course of 
hepatocarcinogenesis (13). PDGF overexpression has been linked to increased 
metastatic potential of HCC, and also acts angiogenic, while bFGF is a mitogen for 
HCC cell proliferation via an autocrine mechanism (13). It enhances the development 
and progression of HCC (13). Upon binding to FGFR-1 it stimulates the release and 
activity of collagenases, proteases and integrins on the extracellular membrane 
leading to the development of microvascular networks  (13). Furthermore, bFGF has 
been shown to synergistically augment VEGF-mediated HCC development and 
angiogenesis (13). High serum levels of preoperative bFGF appeared to be predictive 
of invasive tumorigenesis and early postoperative recurrence (13). 
The glycoprotein130 receptor (gp130) subunit binds to various ligands and is mainly 
involved in inflammatory responses (6). Its downstream signalling can enhance or 
suppress inflammation, since it triggers the recruitment of immune cells to sites of 
inflammation and indcuces the switch from acute to chronic inflammation by 
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recruiting different cell types (6). Upon binding with a member of the multifunctional 
IL-6 family of cytokines it associtates with the IL-6 receptor α (IL-6Rα) subunit into a 
heterotrimer and activates the Jak-Stat-pathway (6). Since this receptor subunit has 
no intrinsic receptor tyrosine kinase activity, constitutively bound cytoplasmatic 
kinases (Janus kinases, Jaks) get activated upon ligand binding, which in turn 
phosphorylate signal transducers and activators of transcription (Stats 1,3,5), with 
Stat3 being the main mediator of IL-6 (8, 19). Also the Ras-Raf-Mek-ERK1/2, MAPK 
and Ras-PI3K/AKT pathways can be activated by gp130 engagement (8, 20). IL-6 
family members are multifunctional cytokines and besides the fact that they are 
crucial mediators of inflammatory responses, they take part in the regulation of 
various cellular oncogenic processes, such as proliferation, apoptosis and 
angiogenesis (7, 21, 22).  
Constitutive activation of IL-6/gp130-Jak-Stat was shown to contribute to 
inflammation-induced tumorigenesis, and since HCC is linked to chronic inflammation 
it is not surprising, that this signalling pathway is often crucially involved (3, 6). One 
example is IL-6 induced acute-phase-response via enhanced expression of Stat3 
target genes in HCC cells, and without Stat3 the acute-phase response was found 
impaired. (22). Also mutations of gp130 leading to constant signalling activity of 
Jak/Stat without cytokine binding were found in inflammation associated HCCs (6, 
23). Besides its contribution to inflammation, IL-6-induced Stat3 activation is involved 
in circumventing apoptosis and growth-stimulation in various cancer cells and was 
further shown to be involved in src-induced transformation (15, 21). 
 
2.5. Intracellular tyrosine kinases in HCC 
Signal transduction form activated cytokine or growth factor receptors is mediated by 
complex cascades of intracellular signalling pathways and molecules including the 
Ras/Raf/MEK/ERK, Ras/PI3K/Akt/mTOR and Jak/Stat pathways (1, 13, 16). Some 
growth factor receptors, such as EGFR, PDGFR and VEGFR transmit their signals 
via src kinase (24). Ras/Raf/MEK/Erk, Ras/PI3K/Akt/mTOR and Jak/Stat-pathways 
mostly transmit proliferation promoting signals (16). Upon phosphorylation of various 
transcription factors gene expression is modulated and posttranslational 
phosphorylation of signalling molecules affects their activity (16). By modulating the 
transcription of Bcl-2 family members or phoshphorylation of Bcl-2, Mcl-1 or caspase 
9 they influence apoptosis regulating pathways (1, 16). Generally, their overactivation 
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leads to upregualtion of molecular players involved in and frequently found in human 
cancer (1, 16). Notably, both hepatitis B and C viruses are able to induce Ras/MAP 
kinase and Jak/Stat pathways (13, 25-28).  
 
Ras regulates various signalling pathways involved in survival, growth and 
proliferation (Fig. 5) (29). While it is tightly controlled normally it is frequently 
deregulated in cancer (29). Almost all HCCs show hyperactivation of the Ras 
signalling cascade, either due to enhanced upstream signalling via growth factor 
receptors, downregulation or promoter hypermethylation of Ras GTPase activating 
proteins (GAPs) such as Rasal-1, NF1 and DAP2IP, or aberrantly overactive 
modulators downstream of Ras (30, 31). Oncogenic mutations of Ras, rendering 
them insensitive to GAPs and thus persistantly activated, are rare (31).   
 
 
Figure 5: Activation and deactivation of Ras and various mitogenic signalling 
pathways operating downstream of Ras (29). 
 
The Raf/MEK/ERK signalling cascade is crucially involved in the development of 
HCC and enhanced activity of this pathway is very frequent (13, 16, 32). Upon ligand 
binding to RTKs such as VEGFR, PDGFR, EGFR and c-Met it transduces growth-
promoting signals to the nucleus (13). Also HCV core protein and HBx can directly 
activate this signalling cascade (13, 33). Raf-1 is frequently overexpressed in HCC, 
and the lack of Raf kinase inhibitor protein was associated with enhanced 
proliferation and migration (13). Since Erk1/2 has hundreds of targets it is not 
surprising that its over-activation influences a variety of cellular programmes like cell 
cycle progression, apoptosis resistance, extracellular matrix remodelling, cellular 
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motility, angiogenesis and resistance to drugs (13, 16). Among transcription factors 
activated by Erk are some for growth-factors and growth-inducing cytokines as well 
as for factors impeding apoptosis (16). In general, Erk activation was associated with 
poor prognosis (16, 28). There exist feed-back loops within the pathway, and 
deregulation mostly contributes to augmented proliferation (16).  
The PI3K/Akt/mTOR protein cascade is another major signalling pathway involved in 
HCC and forwarding signals from RTKs (13). Its activation was correlated with poor 
prognosis, enhanced proliferation and angiogenesis (13, 28) . Among mammalian 
target of rapamycin (mTOR) regulated targets is the translational repressor protein 
PHAS-1/4E-BP, which regulates the expression of VEGF and the translation of 
proteins involved in proliferation and angiogenesis, such as c-myc, cyclin-D1, and 
hypoxia-induced factor 1-α (HIF1α) (13). The enhanced expression of HIF1α entails 
the expression of VEGF, PDGF and thus contributes to angiogenesis (34, 35). Akt 
activates multiple transcription factors and regulators of transcription, like CREB, E2F 
and forkhead transcription factors (16). It further affects murine double minute 2 
(MDM2), which controls the activity of the tumor suppressor p53 (16). Thus, Akt is 
involved in the regulation of survival, proliferation and EMT (16). Also other proteins 
involved in survival and apoptosis pathways are influenced, like the proapoptotic Bcl-
2 associated death (BAD) promoter (16). Also this regulatory pathway has intrinsic 
feed-back loops to limit its activity. The most important negative regulator of this 
pathway is the tumor suppressor phosphatase and tensin homologue deleted on 
chromosome ten (PTEN) (13, 16). It is lost or inactive frequently in human cancers, 
which has severe consequences since it restricts growth promoting signalling by 
degrading phosphatidylinositol-3-kinase (PI3K) products and blocking Akt activation 
(13, 16). It was found to be affected by deletions, promoter hypermethylations, 
mutations or phosohorylation (13, 16). Also in HCC, PTEN is frequently lost or at 
least expressed at diminished levels, and upon PTEN knock-out in hepatocytes, mice 
developed HCC (36). Further negative regulator of the PI3K/Akt/mTOR signalling 
pathway are the scr homology 2 (SH2) domain-containing inositol 5'phosphatases 
SHIP-1 and SHIP-2 (16).  
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2.6. The Jak/Stat-pathway 
The family of janus kinases (Jak) consists of the four members Jak1, Jak2, Jak3 and 
Tyk 2 (14, 22, 37, 38). They are cytoplasmic tyrosine kinases constitutively bound to 
various receptors via their amino terminal domain (FERM) (14, 22, 37, 39). Among 
these receptors are interferon (IFN), growth factor, hormone or cytokine receptors, 
and receptors with gp130- or gamma chain of cytokine receptors (γc) - subunits (14, 
22, 37, 39). Jaks forward signalling from receptors that do not have intrinsic tyrosine 
kinase activity, like the gp130 receptor signalling via Stat (6, 14, 22, 37, 39, 40). The 
diversity of the FERM domain is thought to provide specifity of receptor-binding, and 
further has a regulatory catalytic function (22, 37, 39). The regulation of Jaks is not 
entirely understood, and there are hints that there are still unknown modulators, but it 
is known that their pseudokinase domain has regulatory functions, and mutations in 
this domain can entail hyperactivation (22, 37, 39). Probably it is also involved in the 
recognition of substrates (22, 37, 39). Also the SH2 domain could be involved in Jak 
regulation (22). The kinase domain possesses catalytic activity for tyrosine 
phosphorylation, and is further the site for interaction with negatively regulating 
proteins (Fig. 6) (22, 39, 41).  
 
 
 
Figure 6: The domains of Janus kinases (39). 
 
However, upon ligand-binding to their cognate receptor and subsequent changes in 
localization, like receptor subunit dimerization, Jaks can interact with each other and 
get auto- and transphosphorylated (14, 22, 37, 38). Subsequently, they tyrosine 
phosphorylate the cytoplasmic tail of the receptor, and thereby create a docking-site 
for SH2-containing proteins, such as Stats (13-15, 22, 37, 38). Stats then get 
phosphorylated by Jaks, dimerize and translocate into the nucleus where they 
modulate transcription of their target genes (Fig. 7) (13-15, 22, 37, 38). 
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Figure 7: Activation of the Jak/Stat-pathway (22). 
 
 
Jaks are crucially important for immunity (14, 39, 42). The lack of Jak1 or Jak3 leads 
to severe combined immunodeficiency, and mutations that hinder either the binding 
of Jaks to receptors or inhibit their kinase activity also render the organism with 
immunodeficiencies (14, 39, 42). Since they forward mainly growth promoting 
signals, the activation of Jaks is transient and needs to be tightly controlled (14, 15, 
22, 37, 39). Aberrations in Jak signalling like activating mutations, permanent ligand 
binding, enhanced levels of growth promoting signals or disruption of their negative 
feed-back loops lead to enhanced activity of their substrates and thus changed gene 
expression, which can contribute to several malignancies, such as cancer (6, 14, 15, 
37, 39, 43). Indeed, Jak1, Jak2, mutations were found in several solid cancers and 
blood malignancies which lead e.g. to autonomous cell-proliferation which is a major 
characteristics of cancer cells (1, 6, 44, 45). Phosphorylated Jak1, Jak2 and Tyk2 
were not detected in healthy liver tissue, but in HCCs (13, 31). Aslo the Stat3-targets 
Bcl-xl, Mcl-1, cyclin D1 and c-Myc were found at enhanced levels (13). Interestingly, 
HBV and HCV can activate Jak/Stat-signalling (13, 26). 
The expression of Jak3 was thought to be restricted to the hematopoietic system but 
more recently was also found in several other tissues, among them liver, and in 
epithelial cancers (46, 47). Jak3 activating mutations were found in blood 
malignancies, where they enhanced proliferation, allowed cytokine-independent 
growth, and triggered Jak3 autophosphorylation and subsequent target gene 
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activation (46). By modulating the expression of Bax and Blc-2, and thus contributing 
to the regulation of apoptosis, Jak3 was found to act anti-apoptotic and induce 
survival in T-cells (48). But also in breast and gastric carcinomas Jak3 mutations 
were detected, and both, pharmacological and siRNA-induced Jak3 inhibition could 
prevent EGF-induced Stat3 and ERK phosphorylation in the SKBR3 breast cancer 
cell line (45, 49). Furthermore, a Jak3 inhibitor could hinder Stat3 phosphorylation 
and nuclear translocation upon GH stimulation in C2C12 myoblasts (50). 
Controversially, Jak3 signaling is thought to be restricted to the γc-receptor subunit, 
which is expressed exclusively in hematopoitic tissues (39, 42). Thus, investigation of 
Jak3 functions in non-hematopoitic tissues, and to solve the question if Jak3 could 
bind to receptors beside γc, would be highly interesting. Consequently, we did not 
exclude Jak3 from our experiments. 
 
2.7. Signal transducer and activator of transcription 3 (Stat3) 
A prominent oncogene frequently overactivated by aberrant cytokine signalling is the 
transcription factor Stat3 (14, 15, 39, 51). It is a member of the Stat family of latent, 
cytoplamic transcription factors, comprising 7 members (Stat1, 2, 3, 4, 5a, 5b, 6) (14, 
15, 39, 51). Stat3 consists of an amino terminal, coiled coil, SH-2 domain, a linker 
region, DNA binding and the transcriptional activation domain (TAD) (Fig.8) (39, 41, 
51).  
 
 
Figure 8: Activated Stat3 dimer bound to DNA. (41)  
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Stat3 is involved in a variety of cellular functions like differentiation, growth regulation, 
proliferation, regeneration, inflammation, apoptosis and its functions are tissue-
specific. (13-15, 19, 39, 51) Stat3 is essential in early embryonic development, and 
its inactivation leads to early embryonic lethality (15, 19, 22, 52). Stats are important 
mediators for forwarding growth factor and cytokine signalling. (15, 51, 53) They 
forward signals from growth factor and cytokine receptors and their receptor bound 
Jaks or non-receptor tyrosine kinases (Fig. 9) (15, 51, 53). Stat3 gets quickly 
activated upon stimulation by a wide variety of cytokines like various interleukins, 
growth factors such as EGF and HGF, growth hormone, and oncogenes like v-Src 
which leads to modulation of expression of different gene sets in different tissues (6, 
13-15, 19, 39, 51). The IL-6 family members are among the key inducers of Stat3 (6, 
14, 54). 
 
    
 
 
 
 
 
 
 
 
 
 
 
Figure 9: Activation of Stat transcription factors. (53) 
 
Upon binding to a phospho-tyrosine site on the receptor via their SH2-domain, Stat3 
gets phosphorylated on its tyrosine 705 (pY-Stat3) by receptor associated Jaks, since 
most Stat activating receptors, like the gp130 receptor subunit, have no intrinsic 
tyrosine kinase activity (Fig.9) (6, 14, 15, 39, 53). Still, there are some growth factors 
signalling via intrinsic receptor tyrosine kinases, such as EGFR and PDFR (15, 53, 
55, 56). Then, Stat3 forms homo- or Stat1/3-heterodimers via reciprocal binding 
between the phospho-tyrosine and the SH-domains (6, 14, 15, 51, 53). These 
activated dimers get translocated into the nucleus via importin α5 and Ran, and 
exported upon dephosphorylation (14, 39, 51, 53). Surprisingly, also 
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unphosphorylated monomers were found to be translocated into the nucleus, but 
probably by different mechanisms (39, 57, 58).   
In the nucleus, Stat3 binds to specific DNA sequences and modulates gene 
expression (14, 15, 39, 51, 53). Mostly it induces transcription, but it can also act 
repressive (14). Stat3 homodimers and Stat1/3 heterodimers recognize the GAS 
element, which is an inverted repeat with a 5′-TT(N4–6)AA-3′ consensus sequence 
(14, 39, 54). Stat3 can also recruit co-factors, like co-activators or enhancers, and 
probably gains its gene specifity via promoter-bound proteins (14, 39, 59). It was 
shown to interact with Smads, and Stat3 and c-jun interact and cooperate in 
transcription upon IL-6 stimulation (39, 54, 60). Especially the transcriptional 
activation domain at the COOH-terminal of Stat3 interacts with transcriptional 
complexes, and the possibility of Serine 727 phoshphorylation in the TAD adds 
another level of regulation (15, 39, 61). This phosphorylation is performed by MAP 
kinases and was usually associated with elevated transcriptional activity due to 
enhanced DNA binding, but it was shown that it can also lead to reduced 
transcription (39, 61). However, it creates a further possibility for interaction with 
different transcriptional regulators and the crosstalk with other signalling pathways 
(39). For example, CBP/p300 and c-jun bind to TAD (54, 59, 60). The coiled-coil 
domain is another protein-protein interaction site, where Stat3 can interact with 
transcription factors and regulatory proteins (15, 39, 51, 53, 62).   
Stat3β is a naturally occurring splice variant of Stat3α that lacks the TAD (19, 63). It 
was considered as dominant negative factor which it is not actually, since it is able to 
rescue embryonic lethality of a Stat3 null mutation and to induce expression of Stat3 
specific target genes, like acute-phase genes in the liver and cooperate with c-jun to 
activate transcription (19, 63, 64). Moreover, it can activate and repress genes 
depending on cellular environment and there is evidence that it counteracts the pro-
oncognic activites of Stat3α since its overexpression could decrease BclXL levels, 
induce apoptosis and inhibit cell growth in various cancer cells (19). Additionally, it 
hindered v-src and Stat3-mediated transformation and was able to induce anti-
tumorigenic immune responses (19). Still, the distinct functions and mechanisms by 
which they are executed by Stat3α and Stat3β are not entirely clear. 
Although unphosphorylated Stat3 (U-Stat3) was considered as transcriptionally 
inactive for a long time, it was found to be translocated into the nucleus even without 
being phosphorylated and dimerized (39, 58, 65). Surprisingly, it was further found to 
Introduction 
 21
modulate transcription in cooperation with different factors such as NFκB but its 
putative further functions and interaction partners remain to be elucidated (57).  
However, Stat3 can activate different sets of target genes in different tissues and cell-
types (19, 22). The main targets of Stat3 are proteins involved in cell cycle regulation 
and proliferation, inhibition of apoptosis, induction of angiogenesis and inflammation, 
like cyclins D1/D2 and c-myc, Bcl-XL, Bcl-2 and Mcl-1, MMP-2, MMP-9 and VEGF 
and interleukins (6, 15, 53, 66). Thus, unrestricted activation contributes to 
tumorigenesis and Stat activation is transient and must be controlled strictly to 
prevent unrestricted growth (6, 15, 53). 
 
 
Figure 10: The contribution of Stat3-dependent gene expression to tumorigenesis 
(53). 
 
Normally, the activation of Stat3 is tightly controlled and lasts between some minutes 
to hours (6, 15). In cancer, Stat3 was frequently found to be upregulated or 
constitutively active in several types of solid primary tumors, blood malignancies and 
cells lines, among them HCC (6, 14, 15, 19, 22, 53, 56, 67-71).  Mostly, aberrant and 
persistent activation is due to unrestricted cytokine and growth factor signalling 
mediated by tyrosine kinases (6, 15, 39, 53). It contributes to development and 
progression of cancer by inducing enhanced survival (BclxL, Bcl-2), growth and 
proliferation, angiogenesis, tissue invasion and immune evasion and by inhibition of 
apoptosis (14, 15, 19, 39, 56, 67, 68, 70). Importantly, it is crucially involved in 
malignant transformation, since constitutively active Stat3 is able to induce 
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transformation of NIH3T3 fibroblasts (22, 68, 72). Furthermore, Stat3 was found 
activated in oncogene-transformed cells and even required for src-induced 
transformation and forwarding signals from activated oncogenic non-receptor tyrosine 
kinases, such as v-src (7, 14, 15, 39, 54, 56, 73, 74). Stat3 also contributes to 
cancer-associated inflammation and inflammation-associated tumorigenesis by 
regulating the expression of interleukins and chemokines important to establish a 
cancer-promoting inflammatory environment, and further represses genes for anti-
oncogenic immune stimulation (6, 55, 69). The whole IL6/gp130-Jak-Stat3 pathway is 
an important mediator for tumor-promoting inflammation, which was shown e.g. in 
mice constitutively active in gp130 that developed carcinomas (6). Moreover, in 
chronic inflammation that contributes to tumorigenesis, changes affecting the Stat3 
pathway were found and Stat3-induced expression of IL-6 and growth factors 
expression generates a feed-forward loop leading to even more Stat3 activation in 
the microenvironment (6). Also tumor viruses inducing tumor-promoting inflammatory 
environments, like HBV and HCV activate Stat3 (13, 26). 
In the liver, Stat3 is important for regeneration by inducing survival and cell-cycle 
progression and hinder apoptosis (19, 39). Furthermore, it is needed for the induction 
of inflammatory genes (19). In HCC, Stat3 was found activated in up to 60%, but not 
in healthy livers, and less in tumor-surrounding liver tissue (13, 31, 69, 71, 75). Stat3-
positive tumors were found to be more aggressive and in some studies elevated p-
Stat3 levels could be associated with poor prognosis (13, 69, 71). 
 
2.8. Negative regulation of the Jak/Stat-pathway 
Negative control of signal transduction, and thus, the limitation of signalling is of 
highest importance to prevent unrestricted growth-promoting effects (1). The 
disruption of such control mechanisms required by cancer cells promotes their 
survival, enhanced proliferation and independence on growth factors and cytokines 
(1). Also in HCC, disruption of negative signalling pathways contributes to 
tumorigenesis (5, 14-16). 
Concerning gp130-mediated Jak-signalling, this is performed mainly by the family of 
suppressors of cytokine signalling (SOCS), consisting of the four members SOCS-1, 
SOCS-2, SOCS-3 and CIS (8, 43, 76). They are cytokine inducible inhibitors of 
cytokines, containing a SH2 domain and bind to Jaks and/or receptors and thus, 
inhibit Jak activity or Stat receptor binding (39, 40). Among them, SOCS-1 and 
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SOCS-3 were found to act specifically on the Jak/Stat-pathway (4, 43, 76). Since 
their expression is induced by cytokines and Jak/Stat-mediated signalling, they 
establish a negative feed-back loop (43, 76). By binding to Jaks SOCS inhibit Jak 
activity and further signalling (43). Since no more Stats get activated, which could in 
turn induce the expression of SOCS, the negative regulation gets attenuated after a 
while and the forwarding of cytokine-induced signalling gets possible again (76). CIS 
and SOCS-3 were found to bind to their receptors and thus, inhibits Stat-binding and 
activation (8, 77). SOCS family members probably induce ubiqutinylation, followed by 
degradation of the Jaks or receptors they are bound to (Fig.11) (78, 79).  
 
 
Figure 11: Negative regulation of the Jak/Stat-signal transduction pathway (78).   
 
Epigentetic silencing by promoter hypermethylation of SOCS-1 and SOCS-3 was 
reported in several human cancers, and also in HCC, SOCS-1 was found to be 
affected in 60% and SOCS-3 in 33% (4, 80, 81). SOCS-1 reintroduction in SOCS-1 
silenced cells could suppress Jak-activity and cell growth (43). Interestingly, SOCS-1 
hypermethylation is frequent in HCV-induced chronic hepatitis and cirrhosis, with the 
methylation frequency rising with the stage of fibrosis, the highest found in cirrhosis 
(4, 82). Upon SOCS-3 reintroduction Stat3 phosphorylation was lost, and proliferation 
inhibited (43). Also growth and migration were found to be restricted by SOCS-3 
signalling via inhibition of Jak/Stat-activity (43). Besides, the knock-out of SOCS-3 
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under carcinogenic conditions entailed enhanced proliferation, Stat3 activation, 
inhibition of apoptosis and lead to the development of HCC (43). However, 
downregulation of SOCS is observed in the majority of HCC (31). Thus, SOCS 
proteins are considered tumor suppressors involved in HCC (4, 31, 43). Though 
prolonged pStat3 upon SOCS-3 knock-out and gp130-mediated signalling, the pStat3 
signal gets lost, showing that there are still other mechanisms for negative regulation 
(7). The Src-homology 2 domain-containing phosphatase-1 (SHP-1) also binds to 
Jaks and inhibits their activity by dephosphorylation, and the protein tyrosine 
phosphatase (PTP) CD45 was found to dephosphorylate src and Jak family members 
and thus hinders Stat3 activation, at least in hematopoietic cells (66, 83). Also PTPs 
acting at receptor level and endocytosis of the receptor contributes to limitation of 
cytokine-induced signalling as well as E3 ubiquitin ligases inducing proteasome-
dependent degradation of kinases (14, 53, 83). In the nucleus, protein inhibitor of 
activated transcription 3 (PIAS3) recognizes acitivated Stat3 dimers and hinders 
them from binding DNA and thus from modulating transcription of their targets (14, 
39, 84). PIAS were further found to have E3-ligase activity for sumoylation, so 
possibly Stat3-sumoylation is another regulatory mechanism (85). Besides, there 
exist several protein tyrosine phosphatases which limit the activation of Stat3 and 
thus can induce nuclear export, and also proteolytic degradation of Stat3 is possible 
(15, 53, 66, 86). PTP1b and PTP receptor –T (PTPRT) are still under investigation 
(15, 66, 86).  
 
2.9. Targeting Stat3 
Like other transcription factors known to contribute to tumorigenesis, Stat3 is a target 
of inhibition by various means (6). In fact, interruption of the Stat3 signalling cascade 
by Stat3 knock-down, hindrance of phosphorylation or dimerization entailed 
diminished or inhibited growth in various diverse in vitro and in vivo models (6, 15, 
70). Also apoptosis was observed as a consequence, in some studies even 
exclusively in those cells with activated Stat3 (6, 15). Additionally, non-tumorigenic 
cells or tumor cells without intrinsically activated Stat3 were shown to be less 
sensitive to the used drugs (15). The multi-kinase inhibitors sorafenib and sunitinib 
are the only Stat3 inhibitors used in clinics (6, 13). Sorafenib targets VEGFR and thus 
angiogenesis, PDGFR, FGFR, p38 and Raf kinases and was shown to induce tumor 
growth suppression, diminished proliferation and apoptosis in preclinical studies (13, 
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87). They both induce cell cycle arrest and apoptosis, but it is not entirely clear to 
which extend these effects can be ascribed to the inhibition of Stat3 phosphorylation 
(6). Moreover, since there are multiple and partly redundant signalling networks 
involved in tumorigenesis, the potential danger remains that these inhibitions lead to 
the activation of other oncogenic pathways (1, 6). Stat3 inhibition in tumor cells also 
affects the tumor microenvironment, since it was observed to change tumor-
promoting to tumor-suppressing immune responses (6).  
In HCC cells, downregulation of active Stat3 or Stat3 knock-down could enhance 
chemosensitivity and abolish resistance to ligand-induced apoptosis, the latter effect 
was achieved by sorafenib (87, 88). Further, the inhibition of dimerization and thus 
target gene expression entailed diminished growth of various HCC cell lines in vitro 
and in xenografted mice (89).  
 
2.10. Tumor-suppressive effects of Stat3   
Though well established oncogenic effects of Stat3, there are hints that it also can 
act as tumor suppressor in certain genetic backgrounds (90-92). Evidence for this 
comes from observation in various cancer models. C-myc induced transformation 
was suppressed by a constitutively activated Stat3 construct in mouse embryonic 
fibroblasts (MEFs), but had no effect on Ras-induced transformation (91). Moreover, 
loss of Stat3 in an intestinal cancer mouse model enhanced tumorigenesis but only at 
later stages of tumor development (92). In glioblastoma, Stat3 can have either pro- or 
anti-oncogenic effects dependent on the genetic background of the tumor (90). When 
the tumor suppressor PTEN is missing, knock-out of Stat3 induces transformation of 
astrocytes, and thus is considered to act as tumor suppressor (90). Furthermore, 
upon lack of PTEN Stat3 signalling is impaired in murine astrocytes as well as in 
human glioblastomas (90). On the other hand, Stat3 triggers transformation in PTEN-
positive glial cells, by binding to the oncogenic type III variant of EGFR (90). These 
findings show very clearly how much Stat3 depends on the specific background, and 
how important the understanding of its putative interactions is to prevent adverse 
effects in therapy.  
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2.11. p14ARF 
p14ARF and p19ARF (ARF, human and mouse, respectively) are encoded by the 
CDKN2A locus (human) or INK4a-ARF (mouse) which codes for the two tumor 
suppressor proteins p14ARF and p16Ink4a both involved in cell cycle regulation (93). 
They are controlled by distinct promoters but share exon 2 and 3 in alternative 
reading frames (93, 94). This locus gets activated upon cellular stress, oncogenic 
and aberrant growth stimulatory signalling and was found to be deleted in various 
solid and blood cancers (93-96).  
p16Ink4a controls the activity of the retinoblastoma protein (Rb) and is involved in 
inhibition of cell proliferation (93). p14ARF is upregulated upon sustained 
hyperproliferative signalling, such as oncogenic ras or c-myc and functions as part of 
check-point response since its restricts proliferation by cell cycle arrest or apoptosis 
mainly via the  murine double minute 2 (MDM2, HDM2 in humans)-p53-pathway, but 
also by p53-independent pathways (94-97). Besides, the   locus is associated with 
oncogene-induced senescence (94). The best-known function of p14ARF is the 
stabilization of p53 and thus, induction of cell cycle arrest or apoptosis (93, 96). ARF 
forms a complex with nucleophosmin (NPM) which enhances its stability and locates 
in the nucleolus, where ARF cannot interact with MDM2/HDM2  (93, 94, 96). MDM2 
is an E3 ubiquitin ligase and negatively regulates the transcription factor p53 by 
exporting it into the cytoplasm where it undergoes ubiquitin-mediated degradation 
(93, 94, 96). Upon oncogenic or sustained mitogenic signalling p14ARF binds and 
translocates MDM2 into the nucleus where it gets sequestrated (93, 94, 96, 97). 
Thus, p53 is released and can initiate cell cycle arrest or apoptosis (Fig. 12) (93, 94, 
96, 97). 
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Figure 12: Activation of the tumor suppressive transcription factor p53 to induce cell-
cycle arrest or apoptosis (96). 
 
In various cancers the disruption of this ARF-MDM2-p53 axis was found to be 
impeded frequently (93, 96, 97). Although in HCC the inactivation of p14ARF was only 
found in cancers with functional p53 and thus loss of ARF and p53 were considered 
mutually exclusive and functionally equivalent, ARF also has p53-independent tumor 
suppressor functions (93, 96, 97). It was shown that overexpression of ARF induces 
cell cycle arrest in p53- and MDM2-negative mouse embryonic fibroblasts and there 
are speculations that a distinct ARF isoform could trigger autophagy independently of 
p53, if the p53 pathway is non-functional (96, 98). Moreover, the p53-independent 
translocation of c-myc and thus the inhibition of its potential to activate transcription 
was shown in p53-deficient MEFs (99).    
Importantly, p14ARF has a variety of interaction partners and by this exerts lots of 
different functions (93, 95, 96). There are about 30 described binding partners 
involved in various cellular activites (93, 95, 96). Among them are proteins 
contributing to transcriptional control, like c-myc, E2Fs and Hif1α, chromosomal 
stability and chromatin structure, as well as nucleolar proteins, like NPM and ubiquitin 
ligases, such as MDM2 and Ubc9, which is required for sumoylation (Figure 13) (95). 
Among the p14ARF-mediated effects are sumoylation, like MDM2 or NPM, and 
influencing stability and turn-over of its targets (93, 95, 96). However, binding mostly 
leads to inactivation of interaction partners (Fig. 13, orange), but also ubiquitin- 
dependent (Fig. 13, red) and -independent (Fig. 13, pink) degradation, relocalization 
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and even stabilization and enhanced activation (Fig. 13, green) are possible (95). 
How p14ARF influences its targets is not entirely clear, but also its p53-independent 
anti-oncogenic effects seem to be mainly associated with degradation  (95). 
 
                           
 
Figure 13: ARF binds to a wide variety of factors and affects them in different ways 
(95). Orange denotes inactivation, but also ubiquitin-dependent (red) and –
independent (pink) degradation, and enhanced activity were observed (green) (95). 
 
Since p14ARF is a tumor suppressor which is early and frequently altered in HCC, it is 
considered to be crucially involved in HCC development (100). Biallelic loss, loss of 
heterozygosity, mutations and promoter hypermethylation were found to be 
responsible for the lack of functional p14ARF in HCC (5). Although the CDKN2A locus 
is located in a chromosomal region frequently deleted in HCC, promoter 
hypermethylation is the underlying cause rather than loss or mutation (5, 93, 100). 
Loss occurs seldom in HCC, but hypermethylation was detected in up to 40 % (4, 
100). The p14ARF promoter gets silenced independently of the p16Ink4a promoter and 
hypermethylation may directly precede deletion (5, 100).  Interestingly, methylation or 
mutation of p14ARF are associated with HCV and cirrhosis (43). Promoter 
hypermethylation of p14ARF was found in 6% of HCCs with underlying HCV and 27% 
with underlying HBV infection, and in even 44% cases where alcohol abuse was 
known (101).  
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2.12. The TGF-β/Smad-pathway 
Transforming growth factor (TGF)-β is a powerful cytokine which is mainly important 
for tissue homeostasis and tumor suppression at early stages of tumor development 
(102, 103).  TGF-β inhibits proliferation and induces apoptosis (103). Yet, at later 
stages of tumor progression it can exert opposing effects and promote tumorigenesis 
(103). TGF-β has the potential to enhance the invasive and metastatic potential of 
tumor cells (102, 103). Furthermore, TGF-β can influence the tumor 
microenvironment by generating tumor promoting settings, e.g. by induction of 
angiogenesis or immune suppression (102-104). Besides, TGF-β represents the 
most potent fibrogenic factor (105). Since TGF-β plays crucial roles in proliferation 
and differentiation, it is not surprising that it is required for embryogenesis (102).   
The TGF-β family consists of TGF-β and bone morphogenic protein (BMP) branches 
(106). While the first signal via Smad 2 and Smad3, the latter signal via Smad1, 5 
and 8 (106). All of those and the common Smad (Smad4) contain Mad homology 
regions 1 and 2 (MH1 and MH2), and a linker region between them (106). There exist 
3 isoforms of TGF-β, namely TGF-β1,-β2 and -β3, with TGF-β1 being the one mostly 
implicated in tumorigensis (102).  TGF-β receptors type I (TβRI) and II (TβRII) 
possess serine/threonine kinase activity (103). Upon binding of TGF-β to the TGF-β 
type II receptor, TGF-β type I receptor (also known as ALK5) gets phosohorylated 
and in turn phoshorylates receptor-associated Smads (R-Smads, Smad2, Smad3) at 
2 serin residues in a conserved sequence at the very end of their C-terminal (102, 
106-109). They are released, associate via MH2 with Smad4 into heterodi-or 
heterotrimers and translocate into the nucleus where they modulate transcription of 
genes with TGF-β responsive promoters, among them the inhibitory Smad7 (Fig. 14) 
(102, 106-109). 
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Figure 14: Canonical and non-canonical transduction of TGF-β-induced signalling 
(110). 
 
Smad3 and Smad4 contain a β-hairpin structure in their MH1 domain which binds the 
Smad binding element (SBE) 5′-GTCT-3′ or 5′-CAGA-3′ (108, 111). One or more of 
these SBEs can be found in Smad-responsive promoters (108, 111). The affinity and 
specifity of this binding is weak, so the Smads need to assemble into a transcriptional 
complex to drive gene expression (103, 108, 111). These complexes contain general 
and specific transcription factors, co-activators or co-repressors (103, 108, 111). The 
SBEs are located close to the binding sites of these other transcription factors or 
cofactors, and besides this, Smad-complexes can also bind to some GC-rich 
promoter sequences (108). Interaction with other transcription factors is mediated via 
the MH1 domain while Smad4, transcriptional co-activators or co-repressors bind to 
R-Smads via the MH2 domain (105, 106). Among interacting transcription factors are 
members of forkhead, zinc-finger, homeobox and bHLH families, stabilizing 
transcription factors, such as activating transcription factor2 (ATF2), Jun and Sp1, the 
general co-activator complex CREB-binding protein (CBP)/p300 mediating the 
interaction with general transcription factors, and more smad-specific co-activators, 
like SMIF or Swift (106, 108, 112, 113). The binding to various transcription factors 
with sequence-specific DNA binding and co-factors allows the Smads to form a huge 
amount of different target-gene activating or repressing transcriptional complexes 
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(106, 108, 113). Thus, forwarding of a wide variety of TGF-β1-induced signals leads 
to different context- and cell-type-dependent cellular responses (106, 108, 113). 
Since the Smad interaction partners themselves underlie specific regulations, the 
formation of a functional transcriptional complex is a point of converging with other 
signalling pathways (113). The transcription factor AP1 forms complexes with Smad 
that regulate c-jun, collagenase I and MMP-1 (114, 115). An initial event in TGF-β-
induced growth arrest is the Smad-mediated expression of the cyclin dependent 
kinsase inhibitors p15Ink4B or p21Cip1, which are normally repressed by the oncogene 
c-myc (113). The transcription factor c-myc, which acts activating or repressing 
dependent on its target, is an important repressed target in anti-proliferative TGF-β-
signalling, but also cooperates with Smads to induce oncogenic gene expression 
(103, 106, 116). Also other proteins that are involved in forwarding cell cycle 
progression like Cdc25A phosphatase or the inhibitors of differentiation 1-3 (ID1, ID2, 
ID3) are repressed by TGF-β-Smad und thus exert TGF-β anti-proliferative properties 
(108, 117). On the other hand, the translation inhibitor 4E-BP1 gets expressed upon 
TGF-β signalling and thus, a halt of proliferation is achieved (118). The action of 
TGF-β is highly context dependent, even the transcription of the same target can be 
either activated or repressed by TGF-β dependent on the composition of the Smad 
transcriptional complex (108, 117). An example is the regulation of ID, where first, 
activated Smad3/Smad4 induces the expression of ID and ATF3, and upon sustained 
TGF-β-signalling, the newly expressed ATF3 complexes with Smad3/Smad4, and 
together they repress ID (108, 117). p38 and JNK Map kinases induce the expression 
of ATF3 and thus, interfere with this signalling circuit (108, 117). Besides, the 
PI3/AKT pathway can interfere with the anti-mitogenic activity of the TGF-β pathway 
(119). Phosphorylation of the transcription factor FoxO inhibits the association into a 
complex with Smad3/Smad4 to drive the expression of p21 (119). These examples 
illustrate the lots of opportunities for a crosstalk of TGF β-Smad-signalling with other 
signalling pathways (119). By binding to certain transcription and co-factors Smad3 
can hinder them to perform their function and thus, negatively influence the 
expression of their target genes (108). Furthermore, Smad3 is capable of recruiting 
histone deacetylase 4 and by this induce epigenetic repression of its targets (120).  
TGF-β activates also Smad-independent signalling cascades (Fig.14) (106). It can 
activate the extracellular-signal-regulateted (Erk) kinase, Jun N-terminal kinase 
(JNK), p38 mitogen-activated protein (MAP) kinase, Src kinase and the 
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phosphatidylinositol 3´-kinase (PI3K) pathways.  Furthermore, TGF-β induces the 
activation of Ras via Erk/MAPK signalling and via TGF-β associated kinase 1 
(TAK1)/p38/MAPK signalling (113). Ras and TGF-β can be rivals or colleagues, since 
on the one hand, the activation of Erk/MAP kinase pathway by Ras can trigger the 
inhibition of TGF- β1-induced growth arrest by negatively affecting Smad3 (106, 121). 
On the other hand, Ras and TGF- β1 can act synergistically, since MAP kinase 
signalling is a non-canonical TGF- β signaling pathway (106, 121). In addition, 
Smad2 and Smad3 can be activated independent of TGF- β by stess signals, JNK/c-
Jun- and p38/ATF2-signalling (113). Since pro-inflammatory cytokines activate JNK, 
they can induce Smad2/3-mediated signalling (122, 123).  
Negative regulation of Smad-signalling adds another level of complexity to the TGF-β 
pathways (106, 108) Inhibitory Smads 6 and 7 (I-Smads) compete for receptor 
binding and Smad7 induces receptor I degradation via a smurf-Smad7 complex and 
ubiquitinylation (124, 125). Both I-Smads are induced by the TGF-β family to 
establish a negative feed-back loop (124). While Smad 6 mainly targets the BMP-
pathways, Smad 7 affects members of both family parts (124). Furthermore, Smad7 
is activated by EGF/MAPK- and INF-γ/Jak1/Stat1-pathways and hinders Smad2/3 to 
form complexes with Smad4 (102, 113). Downstream in the signalling cascade, the 
oncogenic protein Ski and SnoN can bind to Smad2, Smad3 and Smad4 and by this 
compete with CBP/p300, disrupt Smad complexes, recruit other co-repressor or 
hinder the binding of co-activators (106, 112). The expression of the Smad co-
repressors Ski and SnoN is induced by TGF-β, and thus causes limitation of TGF-β-
signalling (112). Another protein, SNIP1, hinders the formation of functional 
transcriptional compexes by binding to CBP/p300 and Smad4 (126). In the nucleus, 
R-Smads get dephosphorylated, which causes the dissociation of the transcriptional 
complex and export of its components (108). Degradation is mainly mediated by 
ubiquitinylation (106, 108).  
Besides at their conserved C-terminal serine residues, Smads can also be 
phosphorylated at serine and threonine sites in their more divergent linker region 
(106, 108). This allows a more selective crosstalk with their upstream signals and 
other signalling pathways (108). Among the kinases capable of phosphorylating the 
linker region are the ERK MAP kinases Erk1 and 2, the JNK MAP kinase, CDKs, 
TAK-1 kinase, calcium-calmodulin-dependent protein kinase II and G-protein-coupled 
receptor kinase-2 (122, 127-131). The consequences of Smad-linker phosphorylation 
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are not entirely clear (132). Mostly, diminished translocation and activity were 
reported, like Erk MAP kinase-mediated linker phosphorylation of Smad2 and Smad3 
interfering with nuclear translocation and thus, inhibiting transcription (122, 129, 133). 
On the other hand, Erk-mediated Smad4 linker phosphorylation is followed by 
improved p300/CBP binding and thus, enhances Smad transcriptional activity (134). 
Moreover, linker phosphorylation is associated with oncogenic signalling and cancer 
(108). Besides this, the linker region is the point of interaction with ubiquitin ligases 
(106).  
The TGF-β-Smad pathway and thus its tumor-suppressive function are frequently in 
human cancers (103, 132). The deregulation can affect different parts of the 
pathway. Mutations or loss of TβRI or TβRII, Smad4 or Smad2 were found in 
pancreatic, colon, breast and ovarian carcinomas, gliomas and T-cell lymphomas 
(102, 103). Also epigenetic changes of regulatory components, amplification or 
overexpression of inhibitors or hyperactivation of signalling pathways converging in 
Smad-signalling contribute to tumorigensis (135). Once, TGF-β switched to 
oncogenic acitivity, its own overexpression, the expression of MMP-2 and MMP-9 
and the expression of VEGF induce fibrosis, immune evasion, cell invasion and 
angiogenesis which mainly contribute to tumor promotion (103, 110, 136, 137). TGF-
β is considered to induce epithelial-to-mesenchymal transition (EMT) since 
characteristic morphological changes typical for this process could be observed first 
in rat kidney fibroblasts and later in various carcinoma cell lines exhibited to TGF-β 
(102, 138). TGF-β-induced EMT is accompanied by TGF–mediated expression of 
Snail and Slug (110, 139). TGF-β is also involved in the regulation of cell adhesion. 
(103) First, c-myc and Smad complexes cooperate to enhance the expression of 
snail, and then Smad complexes together with Snail repress epithelial genes, such as 
E-cadherin (140, 141). The evasion from immune surveillance strongly supports 
tumorigenesis, and TGF-β acts as immune suppressor by affecting most cells of the 
innate and the adaptive immune system in their development and function (1, 104, 
112). Among them are macrophages, natural killer cells, and regulatory as well as 
effective T-cells (112). Moreover, TGF-β can induce immune tolerance at high levels 
(112). Since tumors secrete TGF-β and high TGF-β plasma levels are often found in 
patients, this seems to be a common mechanism of tumors to escape from 
destruction by the immune system (102, 112).   
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In the liver mainly hepatic stellate cells produce and secrete TGF-β1, which is 
crucially important in liver regeneration since its anti-mitotic effects terminates 
unlimited hepatocyte proliferation by inhibition of hepatocyte growth factor (HGF) 
(142). In the course of HCC development the TGF-β1-Smad pathway is involved in 
the molecular mechanisms of chronic liver diseases like chronic hepatitis B infection 
and fibrosis, the setup of a tumor-promoting environment, angiogenesis, EMT, 
immune suppression and tumor recurrence (123, 142-144). For example, TGF-β1 
overexpression was observed in fibrosis. (110) The hepatitis B virus protein X was 
shown to shift the pSmad3C isoform towards a JNK-mediated pSmad3L isoform 
resulting in enhanced cell growth and activation of the c-myc pathway (144). 
Additionally to its oncogenic properties, the pSmad3L-pathway acts fibrogenic, since 
it induces extracellular matrix deposition and thus the development of liver fibrosis 
(123). The Smad-interacting protein 1, a transcription factor involved in E-cadherin 
expression control, was found to be silenced in HCC by promoter hypermethylation 
(143).  
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2.13. Aim of the study 
 
Stat3 is a transcription factor known to be activated in malignant hepatocytes that 
contributes to enhanced proliferation and tumorigenesis (31, 51, 69, 71). Since 
tumor-suppressive properties were observed under certain circumstances, e.g. in the 
lack of the tumor suppressor PTEN in glioblastomas, it is an open issue if Stat3 can 
act tumor-suppressive in HCC (90, 91). Because there are clinical efforts to inhibit 
Stat3, it is of highest importance to understand the mechanisms converting Stat3 to a 
tumor suppressor.   
Unrestricted proliferation is a major hallmark capability of cancer and the suppressor 
of hyperproliferative signalling termed p14ARF is lost early and frequently during 
hepatocarcinogenesis (1, 100). Most notably, recent studies revealed that Stat3 
exhibits tumor suppressive effects in HCC cells (145). To clarify the underlying 
molecular changes in Stat3 signalling and characteristics we focused on Stat3 
activation by Jak-mediated tyrosine 705 phosphorylation dependent on p14ARF. First, 
we wanted to know if de novo synthesis is required for IL-6-induced Stat3 
phosphorylation in both p14ARF-positive and p14ARF-negative HCC cells. Next, we 
addressed the question whether Jaks are able to phosphorylate Stat3 in the 
presence or absence of p14ARF. All experiments were performed with two human 
HCC cell lines, both lacking or expressing p14ARF. 
TGF-β and Stat3 are both involved in processes promoting tumorigenesis by 
regulating apoptosis and EMT (1, 6, 15, 112). While TGF-β induces apoptosis at 
early stages of tumor development, Stat3 mediates transcription of anti-apoptotic 
factors of the Bcl-2 family (1, 6, 112). Since the ability to resist apoptotic triggers is an 
important characteristic of cancer cells, we focused on a putative interaction of these 
two players (1). Since we previously found that Stat3 is required to exert TGF-β-
induced apoptosis, we addressed the question whether Stat3 has an impact in the 
canonical TGF-β/Smad signalling by analyzing the nuclear translocation of Smads. 
The cells used for this approach were murine hepatocytes, hepatocytes with delted 
Stat3 and those cells with reintroduced wt-Stat3.  
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3. Materials & Methods 
3.1. Cell lines & Cell culture 
The human hepatocellular carcinoma (HCC) cells Plc/prf/5 (Plc) and Plc/prf/5-p14ARF 
(Plc-p14) cells were used as model system. (145) Plc cells lack p14ARFand express 
mutated p53. Exogenous p14ARF has been reintroduced into these cells by retroviral 
transmission, generating Plc/prf/5-p14ARF cells. In order to accomplish retroviral 
transmission, human Plc cells transiently expressing the wzl-receptor were overlaid 
with a supernatant containing p14ARF-viral particles. (146) Retroviral particles were 
produced from phoenix cells after transfection of the pMSCV plasmid harbouring wild 
type (wt) p14ARF. Transient transfection was performed with SatisFection according to 
the guidelines of the manufacturer (Stratagene, Santa Clara, USA). Ectopic 
expression of p14ARF was detected by Western blot analysis as outlined below. 
Immortalized Plc and Plc-p14 cells were cultivated in DMEM plus 10% fetal calf 
serum (FCS) and 1% antibiotics (penicillin and streptomycin) at 37° C and 5% CO2.  
 
Human Hep3B and Hep3B-sh p14ARF hepatoma cells were employed as a further 
cellular liver cancer model.  Parental Hep3B cells express wild type p14ARF while 
Hep3B-sh p14 ARF_2 and Hep3B-sh p14 ARF_3 cells show each a stable knock-down 
of p14ARF after lentiviral transmission of distinct small hairpin (sh) RNA directed 
against p14ARF. shRNA sequences targeting p14ARF as well as a scrambled control 
were cloned into the pLKO.1 lentiviral vector and Hep3B cells were infected with a 
VSV-G pseudotyped virus by spin infection and subsequently selected with 2 µg/ml 
puromycin. (145) Hep3B cells and their derivatives were cultivated in RPMI 1640 plus 
10% FCS and 1% antibiotics (penicillin and streptomycin) at 37°C and 5% CO2. 
 
Mouse hepatocyte cell lines were generated by isolation of p19ARF-/- hepatocytes from 
p19ARF-/- mice, which lack the 1ß exon of the locus and thus express p16INK4a but not 
p19ARF (MIM-1-4, designated as MIM in the following). (147, 148) Stable retroviral 
transmission of these cells with a construct expressing oncogenic Ras yielded MIM-
Ras cells (MIM-R). (149)  
To obtain cell lines lacking p19ARF and Stat3, p19ARF-/- mice were crossbreed with 
Stat3Δhc mice. (150) Thus, Stat3Δhc/p19ARF-/- double-null mice were generated and 
hepatocytes were isolated and subjected to single cell cloning, resulting in the cell 
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lines MIM-Stat3Δhc-1 and MIM-Stat3Δhc-2. (145) By stable retroviral transmission of a 
construct expressing oncogenic v-Ha-Ras, Ras-transformed MIM-R-Stat3Δhc-2 cells 
were generated. For Stat3 reintroduction, MIM-Stat3Δhc-2 and MIM-R-Stat3Δhc-2 cells 
were subjected to stable retroviral transmission of a construct expressing wtStat3 
(MIM-Stat3Δhc-2-wtStat3, MIM-R-Stat3Δhc-wtStat3. Retroviral transmissions were 
performed as described. (91) Cells were cultured on collagen-coated dishes in RPMI 
plus 10% FCS and 1% antibiotics (penicillin and streptomycin). Additionally, MIM-
derived cells not transformed with oncogenic Ras required the supply with 40 ng/ml 
transforming-growth factor-α (TGF-α) (Sigma, St. Louis, USA), 30 ng/ml insulin-like 
growth factor (IGF-II) (Sigma), and 1.4 nM insulin (Sigma). (151, 152) All cells were 
propagated by splitting 1:4 twice a week and were routinely checked for the absence 
of mycoplasma. 
 
Inhibitor treatment 
3 x 105 (Plc, Plc-p14) or 2,5 x 105 (Hep3B, Hep3B-shp14) cells were seeded per 6-
well to obtain 60-70% confluency overnight. Cell culture medium was changed and 
inhibitors and/or growth factors were added at the indicated concentrations and for 
the indicated time (Table 1). Inhibitors were tested in pilot studies for dose- and time-
dependent efficacy. Inhibitors were used twice as high as the inhibitory concentration 
(IC)50 –values as provided by the suppliers. 
 
Table 1:  Overview of inhibitors used in the study 
Name Inhibition Concentration Time of 
treament 
Company 
actinomycin D transcription 0.1 / 1 µg/ml 24 h Sigma (St.Louis, 
USA) 
cycloheximide translation 1 / 10 µg/ml 24 h Sigma 
Jak-Inhibitor I Jak1-3, 
Tyk2  
(pan-Jak) 
10 ng/ml 1 h Calbiochem Merck, 
(Darmstadt, 
Germany) 
AG490 Jak2 20 µM 24 h Calbiochem Merck 
Jak3 inhibitor 
VI 
Jak3 60 nM 24 h Calbiochem Merck 
AG9 Tyk2 50 µM 24 h Calbiochem Merck 
Materials & Methods 
 38
Table 2: Growth factors used in the study 
Growth factor Name Concentration Time of treament Company 
IL-6 rh-IL-6 20 ng/ml 20 min R&D Systems, 
(Minneapolis, USA) 
 
TGF-ß1 treatment and proliferation kinetics 
1 x 105 MIM, MIM-Stat3Δhc-1, MIM-Stat3Δhc-2, MIM-Stat3Δhc -2-wtStat3, MIM-R and 
MIM-R-Stat3Δhc-2 cells were each seeded in triplicate. Cell culture medium was 
changed and cell number determined every second day in a cell analyser (CASY; 
Schärfe Systems, Reutlingen, Germany). Cumulative cell numbers were calculated 
from all counts and dilution factors. (153) To analyze the influence of TGF-ß1, 1ng/ml 
TGF-ß1 (R&D Systems, Minneapolis, USA) was added to the cell culture medium.  
 
TGF-ß1 treatment for immunofluorescence 
For immunofluorescence analysis, 5 x 104 cells (MIM, MIM-Stat3Δhc-2, MIM-Stat3Δhc -
2-wtStat3, MIM-R, MIM-R-Stat3Δhc-2, MIM-R-Stat3Δhc-2-wtStat3) were each seeded 
per flexiperm-slot on a collagen-coated glass slide to obtain 70-80 % confluency 
overnight. Cell culture medium was changed and 2,5 ng/ml TGF-ß1 were added for 1 
hour. Cells were fixed as described below. 
 
3.2. Immunoblotting 
Preparation of protein extracts  
All steps were performed on ice. After discarding cell culture medium and washing 
the cells twice with ice-cold phosphate buffered saline (PBS), protein extracts were 
prepared using 50 µl RIPA (Radioimmunoprecipitation assay) buffer plus freshly 
added protease- and phosphatase-inhibitors (composition see below) per 6-well. 
Cells were scraped into microcentrifuge tubes, snap-frozen in liquid nitrogen, thawed 
on ice and incubated for 10 minutes prior to centrifugation for 15 minutes at 16.000 x 
g and 4°C. The protein-containing supernatant was transferred into fresh tubes.  
To determine protein concentration, 5 µl of a 1:5 dilution of protein extract are mixed 
with 200 µl Bradford solution (1:5 solution of Bradford stock solution, BioRad, 
Hercules, USA) in a 96-well plate. The resulting color reaction was photometrically 
measured in a microplate reader and protein concentrations calculated by using a 
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calibration curve consisting of bovine serum albumin (BSA) dilutions (0.1, 0.2, 0.4, 
0.6, 0.8, 1.0, 1.2 µg/µl protein). 
Protein extracts were diluted to a concentration of 2 µg/µl with sodium-dodecyl-
sulfate (SDS)-loading buffer (composition see below) and ddH2O, incubated at 95°C 
for 5 minutes, vortexed and loaded on gels.  
 
SDS-polyacrylamide gel electrophoresis 
Separation gels containing polyacrylamide (PAA) with a given percentage were 
generated to separate the protein of interest. The PAA gel was casted between the 
spaced glass plates of the gel casting equipment (Bio Rad, Hercules, USA) and 
overlayed with isopropanol, which was discarded after polymerization.  
 
Separation gel (sufficient for 2 gels) 
 12 % PAA 
ddH2O 4,42 ml 
2 M Tris; pH 8,8 2,25 ml 
30 % PAA / 1%PDA 5,2 ml 
+ 50 µl 10% ammonium persulfate (APS) + 8 µl tetramethylethylenediamine 
 (TEMED, Sigma) 
 
The stacking gel and combs were applied and gel polymerized. 
 
stacking gel (sufficient for 2 gels) 
ddH2O 3 ml 
2M Tris; pH 6,8 0,5 ml 
30 % PAA / 1%PDA 0,5 ml 
+ 20 µl 10% APS / + 4 µl TEMED 
 
Protein samples containing 30 µg protein were loaded and electrophoretically 
separated according to their size at 5 V/cm in a electrophoresis equipment (Bio Rad, 
Hercules, USA) filled up with electrophoresis buffer (composition see below). 
Proteins were blotted on a nitrocellulose membrane at 100 V for 1 hour in a blotting 
equimpment (Bio Rad, Hercules, USA). The blotting chamber contained blotting 
buffer (composition see below), a thermal pack and stirring staff to avoid destruction 
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of proteins due to developing heat. Membranes were stained with Ponceau solution 
to visualize proteins. Membranes were destained with ddH2O before blocking in Tris-
buffered saline-0,1% Tween (TBST)/3% BSA for 1 hour.  
Membranes were incubated with 3 ml primary antibody solutions overnight at 4°C on 
a turntable.  
 
Table 3: Primary antibodies used in the study 
Protein Weight Dilution Blocking reagent Source Company 
pStat3 86, 79 kDa 1:1000 BSA or milk rabbit Cell Signaling  
(Beverly, USA) 
Stat3 86, 79 kDa 1:1000 BSA or milk rabbit Cell Signaling   
Actin 42 kDa 1:2000 TBST rabbit Sigma (St.Louis, USA) 
 
Primary antibodies were collected for re-use and membranes were washed 3 times 
for 15 minutes with TBST before applying 3 ml secondary antibody solution for 1 hour 
at room temperature.  
 
Table 4: Secondary antibody used in the study 
 Dilution  Company 
Peroxidase-conjugated rabbit IgG 1:10.000 in TBST Vector Laboratories 
(Southfield, USA) 
 
The secondary antibody was discarded and membranes were washed 3 times with 
TBST for 15 minutes. 
For signal detection, membranes were incubated with luminol/coumarin working 
solution (composition see below) plus 3 µl/ml 3% H2O2 for 2 minutes, then put into a 
film cassette and developed.  
For reprobing with primary antibodies, membranes were stripped in 3 ml stripping 
solution (composition see below) + 7 µl/ml ß-mercaptoethanol for 30 minutes at 50°C. 
Membranes were extensively washed before proceeding with blocking and 
subsequent incubation with primary antibodies as described above.  
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3.3. Immunofluorescence   
 After washing cells twice with cold PBS for 5 minutes, Histofix 4% formaldehyde-
solution (Roth Lactan, Graz, Austria) was added for 30 minutes at room temperature 
to fix cells. Formaledehyde-solution was to be handled in the extractor hood and 
discarded separately. After washing once with cold PBS for 5 minutes, NH4Cl- 
solution (125 mg/ 50 ml ddH2O) was added for 5 minutes to inactivate the 
formaldehyde-solution and glass slides were gripped in a cassette. To permeabilize 
the membranes, 0,05 % Triton (Roth Lactan, Graz, Austria) in PBS was added for 5 
minutes and afterwards, slides were washed again with PBS for 5 minutes. Next, 
blocking solution consisting of 0,2% fish gelatine (Sigma, St. Louis, USA) in PBS was 
added for 30 minutes before 150 µl first antibody solution was applied for 1 hour.   
 
Table 5: Primary antibody used in this study 
protein dilution source company 
Smad2/3 1:100 in blocking solution mouse BD (Franklin Lakes, USA) 
 
Slides were washed with PBS for 5 minutes. From here on all steps were performed 
in the dark. The secondary antibody mix was applied for 45 minutes and afterwards 
slides were washed three times with PBS and once with ddH2O for 5 minutes each.  
 
Table 6: Secondary antibody solution used in this study 
reactivtiy  name dilution company 
mouse IgG anti-mouse-488-FITS 1:1000 Invitrogen, (Carlsbad, USA) 
actin Phalloidin-TexasRed 1:500 Invitogen 
nuclei Top-pro 1:5000 Invitrogen 
 
Slides were removed from the cassette, covered with moviol (Fluca, Seelze, 
Germany) and a glass top and stored in the dark at 4°C. 
The confocal laser microscope TCS-SP (Leica, Heidelberg, Germany) was used for 
signal detection. 
 
Materials & Methods 
 42
3.4. Buffers, Solutions and Equipment 
RIPA-buffer:  50 mM Tris (pH 7.4) 
                     150 mM NaCl 
                     1 mM ß-glycerophosphat (pH 7.2) 
                      0,5 % DOC (Na-deoxycholate) 
                      1 % Nonidet P-40 
set pH 7.4, store at 4°C 
+ Na3VO4 1mM (inhibition of membrane-bound enzymes) 
+ NaF 1mM (phosphatase inhibitor) 
+ Leupeptin 10µg/ml (protease inhibitor) 
+ Aprotinin 10µg/ml (protease inhibitor) 
+ PMSF 1mM (protease inhibitor) 
storage at -20°C 
5x SDS sample buffer: 250 mM Tris (pH 6.8) 
                                     10 % SDS 
                                      30 % glycerol 
                                      5 % ß-mercaptoethanol 
                                      100 nM dithiotitol 
                                      some crumbs bromphenolblue 
10xTris/glycine: 30g Tris 
                           144g glycine 
                            ddH2O to 1liter 
                            (RT) 
Electrophoresis buffer: 25mM Tris 
                                     192mM glycine (100ml 10xTris/Glycine in 1 liter) 
                                      0,1 % SDS 
                                      (RT) 
Blotting buffer: 25mM Tris 
                        192mM glycine (100ml 10xTris/Glycine in 1 liter) 
                         0,02 % SDS 
                         15 % Methanol 
                         (RT) 
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Luminol/Coumarin working solution: 200ml 0,1 M Tris (pH 8.8) 
                                                          + 500 µl p-coumarin acid (340 ng/26 ml DMSO)  
                                                          + 1ml luminol (2,26 g in 51 ml DMSO) 
                                                          + freshly 3% H2O2 3 µl/ml 
Stripping buffer: 20 nM Tris pH6.8 
                          2 % SDS 
                          (RT) 
                         + ß-mercaptoethanol 7µl/ml  
Primary antibodies: pStat3 (Tyr705) and Stat3 (Cell Signaling, Beverly, USA) 
                               actin and p14ARF (Sigma, St.Louis, USA) 
                               smad2/3 (Invitrogen, Carlsbad, USA) 
                               phalloidin-Texas Red (Invitrogen) 
                               Top-pro-3 iodide (Invitrogen) 
                               store at -20°C 
Secondary antibodies: peroxidase-labelled rabbit IgG (Vector Laboratories,  
                                     Southfield, USA) 
                                     anti-mouse-488-FITS (Invitrogen)  
                                     store at 4°C 
Equipment 
Cell culture plates 96-well, 6-well, 6cm, 10 cm (CytoOne, Orlando, USA) 
Incubator: HERAcell 150i (ThermoScientific, Waltham, USA) 
Light microscope: Nikon TMS (Nikon,Tokyo, Japan) 
Cell counter and analyser system (Schärfe System, Reutlingen, Germany) 
refrigerated centrifuge Megafuge 1.0 R (Kendro Laboratory products, Langensebold, 
Germany) 
microtiter carrier # 2704 (Heraeus instruments, Hanau, Gemany) 
tubes, 15-ml, 50-ml falcons (greiner bio one, Kremsmünster, Austria) 
refrigerated centrifuge 5415R + rotor F45-24-11 (both eppendorf, Hamburg, 
Germany) 
table centrifuge: Sigma 1-3 + rotor 12034 (both Sigma, St.Louis, USA) 
Thermomixer compact (eppendorf) 
Vortex Genie-2 (Scientific Industries, Bohemia, USA) 
Expert Plus Microplate Reader (ASYS, Dornstadt, Germany ) 
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Gel casting equipment, electrophoresis and blotting chamber (BioRad, Hercules, 
USA) 
Turntable Duomax1030 (Heidolph, Schwabach, Germany) 
Hypercassette (Amersham Life Science, Arlington Heights, USA 
BioMaxMS Intensifying screen (Kodak, Rochester, USA)  
Hyperfilm ECL (GE Healthcare, Chalfont St Giles, UK)  
Optimax 2010 X-ray film processor (PROTEC Medizintechnik, Oberstenfeld, 
Germany) 
Histo-cassette rack (Thermo Scientific) 
TCS-SP confocal microscope (Leica, Heidelberg, Germany)
  45
 
Remark:  
 
Parts of the results presented in the following, are published in Schneller D, Machat 
G, Sousek A, Proell V, van Zijl F, Zulehner G, Huber H, et al. p19(ARF) /p14(ARF) 
controls oncogenic functions of Stat3 in hepatocellular carcinoma. Hepatology 2011. 
Contribution to this publication: ascertainment of the need for de novo RNA and 
protein synthesis for Stat3 phosphorylation irrespective of the expression of p14ARF, 
identification of Jak1 as crucial mediator of Stat3 phosphorylation independently of 
p14ARF, development of the model mechanism of nuclear U-Stat3/ARF interaction.
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4. Results 
De novo synthesis of an upstream mediator is required for Stat3 
phosphorylation independently of p14 ARF 
 
To get insights into the regulation of Stat3 tyrosine 705 phosphorylation in the 
presence or absence of p14ARF in the human hepatoma cell lines Plc and Hep3B we 
foremost addressed the question if de novo synthesis is required. Inhibition of 
transcription with actinomycin D as well as inhibition of translation with cycloheximide 
lead to a diminished level of tyrosine 705 phosphorylated Stat3 (pY-Stat3) upon 
stimulation with IL-6. Stat3 itself remained unaffected in Plc cells (Fig. 15A, B). 
Comparable results were obtained in Hep3B cells (Fig. 15C, D). Thus, de novo 
synthesis of an upstream mediator is required to forward the IL-6 signal by tyrosine 
705 phosphorylation of Stat3. Since the loss of the pStat3 signal could be observed 
in Plc and Hep3B expressing or lacking p14ARF, the requirement for de novo 
synthesis is not dependent on the p14 ARF- status in neither of them.  
 
From these data we conclude that de novo synthesis of an upstream mediator is 
necessary for Stat3 705 tyrosine phosphorylation upon IL-6 treatment. However, this 
regulatory event is independent of p14ARF expression. 
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Figure 15 
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Plc-p14 
 
 
 
 
C 
Hep3B 
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D 
 
Hep3B-shp14_3 
 
 
 
 
Figure 15: De novo synthesis is required for IL-6 induced Stat3 tyrosine 
phosphorylation. 
 (A) Plc, (B) Plc-p14, (C) Hep3B and (D) Hep3B-shp14 cells were treated with 
actinomycine D or cycloheximide to block transcription or translation, respectively, for 
24 hours at indicated concentrations (µg/µl). Cells were treated with 20 ng/ml IL-6 20 
minutes prior to cell lysis. Western blots were probed with anti-pY-Stat3, and re-
probed with an anti-Stat3. Actin was used as loading control.  
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Inhibition of Janus kinases (Jaks) abolishes phosphorylation of Stat3 
upon IL-6 treatment 
 
To get a more detailed insight into the mechanism of Stat3 phosphorylation in our cell 
lines, we addressed the question if Janus kinases are necessary to forward IL-6 
signaling and if p14ARF has an influence on that. There are four members of the Jak 
family, Jak1, Jak2, Jak3 and tyrosine kinase 2 (Tyk2), which are known to transduce 
signals from activated cytokine and growth factor receptors. Upon ligand-binding, 
Jaks get phosphorylated and in turn phosphorylate the receptor they are bound to. 
Thereby docking sites for SH2-domain containing proteins like Signal transducers 
and activators of transcription (Stats) are created at the receptor. Upon binding to 
these sites Stat3 gets phosphorylated at its tyrosine 705, dimerizes and translocates 
into the nucleus where it modulates transcription of its target genes (66). To analyze 
wheter Jaks are necessary for this signal transduction, all four Jaks (pan-jak) were 
blocked and the levels of tyrosine phosphorylation of Stat3 upon IL-6 treatment 
evaluated (Fig. 16). This experiment was performed in Plc and Hep3B cells each 
expressing or lacking p14ARF to determine the influence of p14ARF. 
 
Figure 16 
 
Figure 16: Model of pan-jak blocking. To determine the dependence of 
phosphorylation of Stat3 upon IL-6 on Janus kinases, all members of the Jak family 
of kinases were blocked with a pan-jak inhibitor and the effect of IL-6 on Stat3 
phosphorylation was evaluated.  
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Figure 17:  
A 
Plc 
 
 
B 
Hep3B 
 
 
Figure 17: Jak activity is required for IL-6 induced phosphorylation of Stat3. 
(A) Plc cells and two clones expressing p14ARF (plc-p14_1 and plc-p14_2) as well as 
(B) Hep3B cells, sh-control (shc) and two clones not expressing p14ARF  (sh-p14_2 
and sh-p14_3) were treated with either 20 ng/ml IL-6 alone for 20 minutes or pre-
treated with a pan-jak inhibitor (10 ng/ml) for 1 hour. Protein extracts were probed 
with anti-phospho-Stat3 and re-probed with anti-Stat3 antibodies. Actin was used as 
a loading control. 
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Plc cells as well as the two clones expressing p14ARF (plc-p14_1 and plc-p14_2) 
showed a tremendous rise in pStat3 levels upon treatment with IL-6, whereas this 
activation was completely lost after pre-treatment with a pan-jak-inhibitor. The basal 
phosphorylation was diminished as well (Fig. 17A). In the Hep3B cell lines expressing 
or lacking p14ARF, the rise in pStat3 level was also impeded when cells were treated 
with the pan-jak inhibitor, and the basal level was almost lost (Fig. 17B). In both cell 
lines the presence or absence of p14ARF showed no obvious impact on tyrosine 705 
phosphorylation of Stat3. 
 
These data show that Jaks are crucial for transducing IL-6 signals and Stat3 
activation. They further show that p14ARF has no influence on the requirement for 
Jaks to phosphorylate Stat3.  
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Selective blocking of Jak 2, Jak3 or Tyk2 cannot impede phosphorylation 
of Stat3 upon IL-6 treatment 
 
We next analyzed which Jak is responsible for Stat3 tyrosine phosphorylation. 
Therefore, Jak activitiy was inhibited individually and the level of Stat3 tyrosine 705 
phosphorylation (pY-Stat3) upon IL-6 treatment was monitored. To determine a 
putative influence of p14ARF, all experiments were performed with Plc cells, two Plc 
clones expressing p14ARF (plc-p14_1 and plc-p14_2), with Hep3B cells, Hep3B shc 
and two clones with a p14ARF-knockdown (sh-p14_2 and sh-p14_3). Since there is no 
Jak1 inhibitor available, we started with blocking of Jak2 with the inhbitor AG490 
before stimulation of cells with IL-6 (Fig. 18).   
 
Figure 18 
 
 
 
Figure 18: Model of Jak2 blocking. To determine the need for active Jak2 in IL-6 
signal transduction by phosphorlyation of Stat3, Jak2 activation was inhibited and 
phospho-Stat3 levels determined.  
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Figure 19 
A 
Plc 
 
 
 
B 
Hep3B 
     
 
Figure 19: Jak2 inhibition cannot impede IL-6 induced Stat3 phoshphorylation. 
(A) Plc cells and 2 clones expressing expressing p14ARF  (plc-p14_1 and plc-p14_2) 
as well as (B) Hep3B cells, sh-control (shc) and 2 clones not expressing p14ARF (sh-
p14_2 and sh-p14_3) were treated with either 20 ng/ml IL-6 alone for 20 minutes or 
pre-treated with 20 µM of the Jak 2 inhibitor AG490 for 24 hours. Protein extracts 
were probed with anti-phospho-Stat3 and re-probed with anti-Stat3 antibody in 
Western blots. Actin was used as a loading control. 
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The inhibition of Janus kinase 2 had no diminishing effect on the phosphorylation of 
Stat3 upon IL-6 in neither Plc cells lacking nor those expressing p14ARF (Fig. 19A).  
In Hep3B cell lines neither the basal level of pY-Stat3 nor the induction upon growth 
factor treatment could be averted by blocking the activity of Janus kinase 2 (Fig. 
19B). Thus, these data confirm our observations in Plc cells. 
 
Next, Jak3 was blocked with the Jak3 inhibitor VI and cells were stimulated with IL-6 
(Fig. 20).  
 
Figure 20 
 
 
 
Figure 20: Model of Jak3 blocking. Jak3 activity was blocked with Jak3 inhibitor VI to 
determine if it is necessary for Stat3 tyrosine phosphorlyation upon IL-6 treatment.  
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Figure 21 
A 
Plc 
                           
 
 
B 
Hep3B 
               
 
Figure 21: Inhibition of Jak3 cannot impede IL-6 mediated pY-Stat3 phosphorylation. 
(A) Plc cells and 2 clones expressing p14ARF (plc-p14_1 and plc-p14_2) as well as (B) 
Hep3B cells, sh-control (shc) and 2 clones not expressing p14ARF (sh-p14_2 and sh-
p14_3) were treated with either 20 ng/ml IL-6 alone for 20 minutes or pre-treated with 
60nM of a Jak3 inhibitor (Jak3 inhbitor VI) for 24 hours. Protein extracts were probed 
in Western blots with anti-phospho-Stat3 and re-probed with anti-Stat3 antibodies. 
Actin was used as a loading control. 
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The treatment with a Jak3 inhibitor could not change the levels of Stat3 activation 
induced by IL-6 in neither of the cell lines (Fig. 21A, B). Thus, Jak3 is not necessary 
for IL-6 signal transduction, independently of p14ARF. 
 
To determine the influence of Tyk2, its activity was blocked with AG9 before treating 
cells with IL-6 and the levels of tyrosine phosphorylated Stat3 were evaluated (Fig. 
22). 
 
 
Figure 22 
 
 
 
 
Figure 22: Model of Tyk2 blocking. Tyk2 was blocked with AG9 to determine its 
impact on IL-6 induced phosphorlyation of Stat3. 
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Figure 23 
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Figure 23: Tyk-2 inhibition cannot impede the phosphorylation of Stat3 upon IL-6 
treatement. (A) Plc cells and 2 clones expressing p14ARF (plc-p14_1 and plc-p14_2)  
as well as (B) Hep3B cells, sh-control (shc) and 2 clones not expressing p14ARF (sh-
p14_2 and sh-p14_3) were treated with either 20 ng/ml IL-6 alone for 20 minutes or 
pre-treated with 50µM of the Tyk2 inhibitor AG9 for 24 hours. Protein extracts were 
probed with anti-phospho-Stat3 and re-probed with anti-Stat3 antibody in Western 
blots. Actin was used as a loading control. 
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Blocking Tyk2 activity had no effect on the phosphorylation of Sta3 upon IL-6 
treatment in none of the employed cell lines, and thus is not needed for signal 
transduction independently of the expression of p14ARF (Fig. 23A,B). 
 
Together, from these data we conclude that neither Jak2, nor Jak3 or Tyk2 are 
necessary for tyrosine 705 phosphorylation of Stat3 upon IL-6 treatment, 
independently of p14ARF. Thus, Jak1 is considered the responsible kinase for the 
transduction of IL-6 signaling. These results further suggest that the Jak1-mediated 
phosphorylation of Stat3 upon IL-6 stimulation is independent of the expression of 
p14ARF.  
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Blocking of Jak2, Jak3 and Tyk2 cannot impede phosphorylation of Stat3 
upon IL-6 treatment 
 
To exclude an accumulative effect of single inhibitors and thus proof the need for 
active Jak1, Plc and Hep3B cell lines each expressing or lacking p14ARF, were pre-
treated with Jak2, Jak3 and Tyk2 inhibitor and analyzed for p-Stat3 activation after IL-
6 stimulation (Fig. 24).  
 
Figure 24 
 
 
 
Figure 24: Model of combined Jak2, Jak3 and Tyk2 inhibition. Jak2, Jak3 and Tyk2 
were inhibited with AG490, Jak3 inhibitor VI and AG9, respectively, to examine the 
requirement of Jak1 for Stat3 phosphorylation. 
 
 
Results 
 60
Figure 25 
A                                                                    B 
                             
   
Figure 25: Jak2, Jak3 and Tyk2 inhibition together fails to reduce IL-6 induced 
phosphorylation of Stat3. (A) Plc and plc-p14_1 cells as well as (B) Hep3B and 
Hep3B sh p14_3 cells were treated with 20 µM Jak2 inhibitor AG490, 60nM Jak3 
inhibitor VI and 50µM Tyk2 inhibitor AG9 for 24 hours and supplied or not with 20 
ng/ml IL-6 20 minutes before preparation cell lysis. Protein extracts were probed in 
Western blots with anti-phospho-Stat3 and re-probed with anti-Stat3 antibody. Actin 
was used as a loading control. 
 
According to the settings where each kinase was inhibited alone, the elevation of pY-
Stat3 upon IL-6 could not be hindered by combined inhibition of Jak2, Jak3 and Tyk2. 
Again, this was independent of p14ARF expression in both employed cell lines (Fig 
25).  
 
Taken together, we assume that Jak1 is the kinase crucial for tyrosine 705 
phosphorylation of Stat3 in Plc and Hep3B hepatoma cell lines. Further, our data 
show that Stat3 phosphorylation is independent of the expression of p14ARF in vitro. 
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Stat3 is a mediator for anti-proliferative effects of TGFβ1 
 
We addressed the role of TGF-β1 in the proliferation of Stat3-deficient immortalized 
hepatocytes and those transformed with oncogenic Ha-Ras. Immortalized MIM cells, 
those lacking Stat3 (MIM-Stat3Δhc -1 and MIM-Stat3Δhc -2) or Stat3-deficient 
hepatocytes with reintroduced wild type Stat3 (MIM-Stat3Δhc -2-wtStat3) were 
cultivated end administrated with TGF-β1.  
 
Figure 26 
 
Figure 26: Lack of Stat3 prevents anti-proliferative effects of TGF-β1. Proliferation 
kinetics of MIM cells, MIM-Stat3Δhc -1 and MIM-Stat3Δhc -2 cells lacking Stat3 and 
MIM-Stat3Δhc -2-wtStat3 with reintroduced wild-type Stat3 exposed to TFG-β1 (1 
ng/ml). These data are provided by Doris Schneller (PhD thesis, 2010). 
 
While TGF-β1 acted anti-proliferative on MIM cells as expected, MIM cells lacking 
Stat3 (MIM-Stat3Δhc-1 and MIM-Stat3Δhc-2) were insensitive to these effects (Fig. 26). 
Reintroduction of wtStat3 (MIM-Stat3Δhc -2-wtStat3) rescued the phenotype and cells 
became sensitive to TGF-β1-mediated growth arrest again. These results suggest 
that Stat3 is an important mediator of TGF-β1 effects.  
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To further address the influence of oncogenic Ras, the Ras-transformed cell lines 
MIM-R and MIM-R-Stat3Δhc-2, where Stat3 has been knocked-out, were cultured in 
the presence or absence of TGF-β1 and proliferation kinetics were performed.  
 
Figure 27  
 
Figure 27: Lack of Stat3 induces insensitivity to TGF-β1. Proliferation kinetics of Ras-
transformed MIM cells lacking or expressing Stat3 (MIM-R and MIM-R-Stat3Δhc-2, 
respectively) and each treated with TGFβ1 (1 ng/ml) (MIM-R+TGFβ1 and MIM-R-
Stat3Δhc-2+TGFβ1). These data are provided by Doris Schneller (PhD thesis, 2010). 
 
MIM-R cells expressing or lacking Stat3 showed no significantly different proliferation 
kinetics (Fig. 27). TGF-β1 treatment of MIM-R cells lead to strongly reduced 
proliferation compared to MIM-R cells not exposed to TGF-β1. According to the data 
from MIM cells lines, MIM-R cells without Stat3 (MIM-R-Stat3Δhc -2) were less 
sensitive to TGF-β1 and their proliferation was significantly higher. Indeed, their 
proliferation did not vary significantly from MIM-R-Stat3Δhc -2 not treated with TGF-β1. 
These results indicate a crucial role of Stat3 in the execution of TGF-β1 induced anti-
proliferative effects.  
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Stat3 affects the abundance but not the translocation of Smad2/3 upon 
TGF-β1 treatment 
 
Since Stat3 seems to be an important mediatior of anti-proliferative TGF-β1 effects, 
the question arose wheter the nuclear translocation of Smad2/3 is affected by the 
loss of Stat3. To address this question, MIM cells and Ras-transformed MIM cells 
(MIM-R) as well as those with a Stat3 knock-out (MIM-Stat3Δhc-2 and MIM-R-
Stat3Δhc-2) and a reintroduced wild type Stat3 (MIM-Stat3Δhc -2-wtStat3 and MIM-R-
Stat3Δhc -2-wtStat3) were treated with TGF-β1 and Smad2/3 localization was 
determined by immunofluoresence microscopy.  
 
Figure 28 
 
 
Figure 28: Lack of Stat3 entails less nuclear Smad2/3 upon TGF-β1 treatment. 
MIM cells, MIM cells with a Stat3 knock-out (MIM-Stat3Δhc-2) and a reintroduced 
Stat3 wild type construct (MIM-Stat3Δhc -2-wtStat3) were treated with 2,5 ng/ml TGF-
β1 for 1 hour. Untreated control cells (upper panel) and TGF-β1-treated cells (lower 
panel) were probed with a Smad2/3 antibody (green), To-Pro3 to localize nuclei 
(blue) and Phalloidin for actin-staining (red). 
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MIM, MIM-Stat3Δhc-2 and MIM-Stat3Δhc-2-wtStat3 did not differ in neither amount nor 
localization of Smad2/3 in the untreated condition. There was a comparable basal 
level of the protein localized in the cytoplasm (Fig. 28, upper panel). Upon TGF-β1 
treatment, Smad2/3 localized and accumulated in the nucleus in MIM cells, which 
was also observed in MIM-Stat3Δhc-2 lacking Stat3 but with a clearly less amount of 
Smad2/3. When Stat3 was reintroduced (MIM-Stat3Δhc-2-wtStat3), the levels of 
nuclear Smad2/3 were enhanced again (Fig. 28, lower panel). Thus, we conclude 
that Stat3 is rather involved in Smad2/3 expression than localization upon TGF-β1 
treatment in MIM cells.  
 
Figure 29 
 
 
Figure 29: Lack of Stat3 results in less Smad2/3 expression. MIM-R cells, MIM-R 
cells with a Stat3 knock-out (MIM-R-Stat3Δhc-2) and a reintroduced Stat3 wild type 
construct (MIM-R-Stat3Δhc -2-wtStat3) were treated with 2,5 ng/ml TGF-β1 for 1 hour. 
Untreated control cells (upper panel) and TGF-β1-treated cells (lower panel) were 
probed with a Smad2/3 antibody (green), To-Pro3 to localize nuclei (blue) and 
Phalloidin for actin-staining (red). 
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MIM-R cells lacking Stat3 (MIM-R-Stat3Δhc-2) showed a less amount of cytoplasmic 
Smad2/3 than MIM-R cells expressing Stat3. This could not be rescued by the 
reintroduction of a Stat3 wild type construct (MIM-R-Stat3Δhc-2-wtStat3) (Fig. 29, 
upper panel). Upon TGF-β1 treatment, Smad2/3 localized and accumulated in the 
nucleus in all three cell types but in clearly different amounts. While in MIM-R cells 
nuclear signals could be observed, in MIM-R-Stat3Δhc-2 only very little Smad2/3 was 
detected in the nuclei and this only at the borders of the cell layer. When Stat3 was 
reintroduced (MIM-R-Stat3Δhc-2-wtStat3), more Smad2/3 was found in the nuclei 
again, but not as much as in the initial condition. Again, Smad2/3 positive cells were 
those at the borders (Fig. 29, lower panel).  
 
These results show that Stat3 might play a role in the expression of Smad2/3 also in 
Ras-transformed MIM-R cells, but not in the translocation upon TGF-β1 treatment. 
Interestingly, the reintroduction of Stat3 in MIM-R cells could not rescue the 
phenotype in the same extend as in MIM cells.  
 
Taken together, our results suggest that Stat3 plays a crucial role as a mediator of 
TGF-β1-induced effects in both, untransformed and Ras-transformed hepatocytes. 
Lack of Stat3 caused insensitivity to the anti-proliferative effects of TGF-β1 which 
might be linked to the level of nuclear Smad2/3 upon TGF-β1 treatment.
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5. Discussion  
Recent findings revealed that Stat3, so far considered as an oncogene, could also 
act in a tumor-suppressive manner dependent on the expression of p14ARF. In the 
presence of p14ARF it exerts its well-known tumor-pomoting properties while in the 
absence of p14ARF it was found to act tumor-suppressive in in vivo models. (145) 
Mouse hepatocytes expressing p14ARF and harbouring a transcriptionally constitutive 
active variant of Stat3 resulted in augmented tumors when injected subcutaneously 
into SCID mice, while mouse hepatocytes lacking p14ARF and harbouring also this 
construct entailed smaller tumors than the respective controls. When a U-Stat3 
construct which cannot be phosphorylated due to a Y705F mutation was introduced 
into the p14ARF-lacking cells, a tremendous rise in tumor growth could be observed, 
indicating a tumor-suppressive role of activated Stat3 in a p14ARF-deficient 
background. The human HCC cell line Hep3B where p14ARF had been knocked down 
showed no change in tumor growth but the phosphorylation of Stat3 was lost in tumor 
tissue indicating the circumvention of Stat3s tumor-suppressing effects without 
p14ARF (145).  
To achieve mechanistic understanding of these processes we were interested 
whether p14ARF has an influence on the activation of Stat3. First, we addressed the 
question if de novo RNA and/or protein synthesis is necessary for Stat3 tyrosine 
phosphorylation and if this is influenced by p14ARF. Inhibition of transcription or 
translation showed very clearly that de novo RNA and protein synthesis are required 
for phosphorylation of Stat3 upon growth factor stimulation with IL-6 in cell lines 
expressing or lacking p14ARF (Fig. 15A-D). Thus, the requirement for de novo 
synthesis is independent of p14ARF. Interestingly, in Plc cell lines the levels of Stat3 
remain unaffected by inhibition of de novo synthesis, while in Hep3B cell lines the 
inhibition of transcription reduces Stat3. This indicates a possibly different stability of 
Stat3 between these cell types, which could be due to different deregulation of 
physiological mechanisms. Nevertheless, also in Hep3B cells there remains sufficient 
Stat3 to be phosphorylated. Thus, the absence of a molecule triggering 
phosphorylation is thought to be responsible for the attenuation of pY-Stat3 levels. 
This crucial mediator of phosphorylation is likely a tyrosine kinase positively 
regulating pStat3 levels but could also be another element of the Stat3 signaling 
network. Actually, it could concern a component interfering with one of the negative 
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regulators of Stat3 which are responsible for fine-tuning the extent and duration of 
Stat3 phosphorylation. This affected enzyme could imaginably be a tyrosine 
phosphatase like Src homology 2 domain-containing protein tyrosine phosphatase 1 
(SHP-1), which directly interacts and dephosphorylates Jaks, or protein tyrosine 
phosphatase receptor-T (PTPRT), which specifically dephosphorylates Stat3 and can 
act as tumor suppressor (66, 154). Also a member of the family of suppressors of 
cytokine signaling (SOCS) could be affected. Their degradation is regulated tightly 
and if some required molecule was no longer expressed and thus SOCS were no 
longer negatively regulated Jaks would get deactivated and Stat3 could no longer be 
phosphorylated (155). However, the lack of an inhibitory component could lead to 
unlimited action of these pY-Stat3 suppressors resulting in diminished pY-Stat3 
levels.  
The kinases coming into consideration first for forwarding the IL-6 signal and 
phosphorylating Stat3 are the members of the Janus family of kinases Jak1, Jak2, 
Jak3 and Tyk2 (38).  Jak3 was long thought to be exclusively expressed in the 
hematopoeitic system, but it was found to be mutated in breast and gastric 
carcinomas and to contribute to EGF-signalling in a breast cancer cell line (45, 49). 
Thus, we investigated the requirement of each and addressed the question whether 
the expression or absence of p14ARF has an impact on their function in activating 
Stat3. When we pharmacologically blocked the activity of all Jaks, Stat3 
phosphorylation upon IL-6 was hindered in all employed cell lines. In both cell lines, 
Plc and Hep3B also the basic level of pY-Stat3 was diminished by pan-jak inhibition 
(Fig. 17A,B).  These effects are independent of the expression of p14ARF. These 
results indicate that in fact Janus kinases are responsible for the tyrosine 705 
phosphorylation of Stat3 and that they are independent of p14ARF in vitro.  
Further investigations which Jaks contribute to Stat3 phosphorylation revealed that 
neither Jak2, nor Jak3 or Tyk2 are crucial in this process, since IL-6 treatment 
entailed enhanced pY-Stat3 levels despite inhibition of the respective kinase (Fig. 19, 
21, 23). Notably, again we observed comparable results in all employed cell lines 
irrespective of p14ARF expression. Since the inhibition of Jak1, Jak2, Jak3 and Tyk2 
together negatively influenced pY-Stat3 levels basically and upon treatment with IL-6, 
but the inhibition of Jak2, Jak3 or Tyk2 alone did not, we concluded that Jak1 is 
responsible for the phosphorylation of Stat3 in hepatocytes, irrespective of p14ARF. To 
exclude a collaborative effect of Jak2, Jak3 and Tyk2 and to underscore the 
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importance of Jak1, we inhibited Jak2, Jak3 and Tyk2 together. According to the data 
observed until then, this combined inhibition could not impede Stat3 phosphorylation 
upon IL-6 treatment irrespective of p14ARF (Fig. 25). This corroborates our 
supposition that Jak2, Jak3 and Tyk2 are negligible for tyrosine phosphorylation of 
Stat3. Considering all obtained data we ascribe Jak1 the responsibility for Stat3 
tyrosine705 phosphorylation in hepatocellular carcinoma cell lines expressing or 
lacking p14ARF (Fig. 30).  
 
 
Figure 30: Jak1 forwards IL-6 signalling by phosphorylation of Stat3.  
 
To proof this assumption the selective inhibition of Janus kinase 1 would be 
necessary. Since there is no pharmacological Jak1 inhibitor available, the use of a 
small interfering (si) or small hairpin (sh) RNA targeted against Jak1 on a cellular 
level or a Jak1 knock-out could be performed. Since the lack of Jak1 is not 
embryonically lethal the deletion of Jak1 in mice is possible and has been done 
already (156). However, the lack of Stat3 is embryonically lethal and so the suspicion 
arises that in a Jak1-deficient mouse other Jaks would fill in for the missing Jak1 in 
order to phosphorylate Stat3 (156). Generally, it would be interesting if and under 
which conditions/ circumstances Stat3 would be activated by the other members of 
Jaks in hepatocytes. To confirm that the de novo synthesis of Jak1 is required for 
Stat3 phosphorylation, the purified kinase could be introduced in transcription- or 
translation-blocked cells by microinjection. The introduced kinase should then rescue 
the phenotype and pY-Stat3 levels would be unaffected. Unfortunately, there are 
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major technical limitations to this method, namely that only single cells can be 
injected. Thus, an inducible construct harbouring Jak1 would be useful. Since 
transcription and translation are required to express the exogenous kinase the 
question asked above could not be addressed, but still, we should observe major 
differences in pY-Stat3 levels, while the hyperactivation of the other family members 
should not have the same impact. Another possibility to emphasize the mechanistic 
role of Jak1 in Stat3 activation would be to correlate active Stat3 with active Jak1. 
Unfortunately, the available phospho-Jak1 antibodies did not work properly in our cell 
lines.  Still, we consider Jak1 as the crucial kinase for Stat3 tyrosine phosphorylation 
in HCC cell lines and, importantly, found that p14ARF had no influence on Stat3 
activation in vitro. Thus, we state that the impact of p14ARF conveying tumorigenic 
properties to Stat3 in vivo is located downstream of Stat3 phosphorylation.  
If p14ARF is expressed in vivo, Stat3 gets phosphorylated by Jak1, dimerizes, 
translocates into the nucleus and performs its oncogenic action as do introduced 
transcriptionally constitutive active (ca) Stat3 constructs. Also unphosphorylated 
Stat3 (U-Stat) is able to enter the nucleus but has no impact on tumor development in 
this genetic background (57) (Fig. 31A). In the case that p14ARF is missing, the 
situation changes dramatically. Ca-Stat3 expression leads to diminished tumor 
growth, thus Stat3 acts anti-oncogenic. Concomitant, pY-Stat3 levels are decreased 
in tumor tissue to circumvent further anti-oncogenic effects. U-Stat3 again enters the 
nucleus, and this time without p14ARF this results in strongly enhanced tumor growth. 
Therefore, we assume that U-Stat3 interacts with a so far unidentified factor, termed 
ARF-X, to drive gene expression (Fig. 31B). This factor is thought to be occupied by 
p14ARF under physiological conditions, since p14ARF is known to interact with a variety 
of partners, including transcription factors (Fig. 31) (95). Thus, finding ARF-X would 
be of high priority.  
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Figure 31: Model of pro- and antioncogenic actions of Stat3 depending on p14ARF. 
(A) When p14ARF is expressed, Stat3 gets phosphorylated by Jak1 and performs its 
pro-oncogenic action. ARF-X is occupied by p14ARF and thus, U-Stat3 remains 
trancriptionally inactive. (B) In the absence of p14ARF, phosphorylation of Stat3 is 
circumvented and U-Stat3 drives oncogenic gene expression in concert with ARF-X. 
Ca-Stat3 dimers turn on the expression of genes with anti-oncogenic effects.  
 
To ascertain if in fact the inhibition of Jak1 is responsible for the reduced pY-Stat3 
levels in tumor tissues lacking p14ARF these tissues need to be probed with a 
phospho-Jak1 antibody. To find the putative U-Stat3 binding partner ARF-X co-
immun-precipitation of these two proteins could be performed by fishing for U-Stat3 in 
a p14ARF – negative background. Though, a strong binding between them is a 
precondition for this approach and we do not know about the strength of this 
interaction.  
Stat3 was found to hinder transformation in the absence of tumor suppressors like 
PTEN or p53 in glioblastoma or rodent fibroblasts, respectively, and thus to act as 
tumor suppressor in these genetic backgrounds (90, 91). In our case, we can exclude 
that the tumor suppressive effect of Stat3 is ascribed to the lack of p53, since on the 
one hand the used p14ARF-/- cell lines show an active p53 response and on the other 
Hep3B cells harbour a p53 mutation, but in both a tumor suppressive effect of Stat3 
in the absence of p14 ARF was observed (157, 158). Since Hep3B cells express 
PTEN, the tumor suppressive effect of Stat3 can not be rooted in its lack (159, 160). 
The finding that caStat3 leads to diminished tumor growth when p14ARF is lacking, 
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raises the question which different set of genes mediates this effect and how Stat3 is 
able to turn on their transcription. It would be of interest how Stat3 is directed towards 
these promoters and if there are putative interaction partners that do so.  Despite a 
different set of genes, the different outcome in this setting could also be rooted in 
different effects of the transcribed target genes, potentially involving the tumor-
microenvironment. For example, the constitutive activation of the Stat3 target and 
oncogene myc can indirectly promote senescence and apoptosis in lymphoma 
mouse models with involvement of tumor-surrounding non-malignant cells which 
secrete cytokines in response to the constantly activated myc (55, 161). A similar 
non-cell-autonomous tumor suppression mechanism could be imagined in the case 
of constitutively activated Stat3, which somehow only takes effect if p14ARF is 
missing.  
Moreover, p14ARF influences the levels of pY-Stat3 in vivo but not in vitro and 
obviously Stat3 activation is affected via a still unknown feed-back loop if it turns out 
to act anti-oncogenic. This, together with the fact that the absence of p14ARF converts 
the pro-oncogenic properties of Stat3 into anti-oncogenic ones guides the 
considerations about mechanistic sequences towards a putative participation of the 
tumor-microenvironment in these processes. Non-malignant cells that are recruited to 
the tumor and act out a variety of supportive functions like growth factor secretion 
could be involved in those mechanisms (1). To figure out which cells are involved and 
bring to light the underlying mechanisms of tumor-stroma interactions contributing to 
the switch of Stat3 being pro-or anti-oncogenic would be a surely challenging but 
worthwhile purpose.  
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TGF- β1 stimulates tumor progression at later stages of tumor development but has 
tumor-suppressive effects in early tumorigensis (106). During early stages TGF- β1 
inhibits cell growth and induces apoptosis. (106) Since TGF-β1 can execute different 
cellular programs during the course of tumorigenesis, it is of highest priority to 
understand the underlying mechanisms and which players are involved in either 
mode of TGF-β1 action. We were particularly interested in a putative cooperation of 
Stat3 and TGF- β1 in tumorigenesis, namely the control of cell cycle progression on 
the one hand, and survival and apoptosis on the other. MIM hepatocytes as well as 
Ras-transformed MIM cells (MIM-Ras, MIM-R) were employed. 
When MIM cells were exposed to TGF-β1, it exerted its anti-proliferative effect as 
expected. Interestingly, cells lacking Stat3 (MIM-Stat3Δhc -1 and MIM-Stat3Δhc -2) 
were insensitive to growth-inhibition and induction of apoptosis by TGF- β1. To prove 
the crucial importance of Stat3, a wild-type construct was introduced in the Stat3Δhc 
cells and indeed, the phenotype was partially rescued. The cells did not restore 
proliferation arrest without an increase in proliferation kinetics (Fig. 12). Thus, we 
considered Stat3 an important mediator of TGF-β1-mediated effects, namely TGF-
β1-induced cell death and cell cycle arrest. This opened the question whether Stat3 
affects the canonical TGF-β1 signalling cascade. 
In MIM-Ras cells, TGF-β1 treatment does not lead to cell death, but entails 
significantly slower proliferation. In these cells the lack of Stat3 had no influence on 
proliferation, since untreated cells without Stat3 showed no significantly different 
kinetics from untreated cells expressing Stat3. Stat3-deficient cells seem to be 
resistant to TGF-β1 mediated effects, since in these cells and untreated Stat3Δhc cells 
no significantly different cumulative cell numbers were observed. Stat3-deficient cells 
treated with TGF-β1 were clearly less sensitive to its growth hindering effects than 
cells expressing Stat3, since there was a significant difference in their proliferation 
kinetics. Upon oncogenic Ras transformation, Stat3 seems to be important for the 
reduction of proliferation kinetics upon TGF-β1 treatment. Again the question arose 
where Stat3 influences the signal transduction cascade following the exposure to 
TGF-β1. 
Interestingly, TGF-β1 treatment induced apoptosis in untransformed MIM cells, but 
lead to cell cycle arrest in Ras-transformed MIM cells. In both cell lines the lack of 
Stat3 induced insensitivity to TGF-β1 (Fig.12, 13). These findings indicate that (i) 
MIM-R cells gained the ability to evade apoptosis by Ras transformation, and (ii) the 
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forwarding of the TGF-β1-signal relies on Stat3 irrespective of Ras. To complete 
these observations it would be necessary to show the effect of a reintroduced wt-
Stat3 construct on proliferation kinetics of MIM-R cells treated with TGF- β1. 
 
In a next step, we addressed the question how Stat3 affects the TGF-β1 signalling 
cascade. Since Smad signalling is the canonical signal transduction pathway of TGF-
β1, we focussed on receptor-mediated Smad2/3 translocation into the nucleus and 
investigated if Stat3 is required (103). 
In untreated MIM cells, a cytoplasmic distribution of Smad2/3 in comparable amounts 
was observed irrespective of the presence or absence of Stat3 (Fig. 14, upper panel).  
Upon TGF-β1 treatment, MIM cells exposed strong signals in their nuclei, but 
surprisingly only at the periphery of collected cells, while a complete lack in cells 
surrounded by others was observed. Without Stat3, translocation into the nucleus 
was still induced, but the amount of Smad2/3 was found to be clearly reduced. Upon 
reintroduction of a wt-Stat3 construct we observed a dramatically elevated amount of 
Smad2/3, most of it located in nuclei (Fig. 14, lower panel). Thus, the lack of Stat3 
did not hinder translocation, but seemed to negatively influence the abundance of 
Smad2/3 in MIM cells. The assumption that Stat3 modulates Smad2/3 transcription 
was supported by rise of Smad2/3 levels upon Stat3 wild type introduction. 
When we looked for a putative change in the translocation capacity of Smad2/3 upon 
TGF-β1 treatment in MIM-Ras cells, we found less Smad2/3 expressed when Stat3 
was lacking even in untreated MIM-R cells.  Further, the introduction of a wt-Stat3 
construct could not totally rescue that phenotype (Fig. 15, upper panel). Upon 
exposure to TGF-β1, all Smad2/3 was translocated into the nuclei in wt-MIM-R cells. 
In cells lacking Stat3 we could detect only a small amount of Smad2/3, which was still 
translocated into the nuclei, but only at the borders of the cell layer. Reintroduction of 
wt-Stat3 increased the amount of Smad2/3, but not as much as in MIM cells. Again, 
translocation was observed at the borders of the cell layer (Fig. 15, lower panel). 
Taken together, also for Ras-transformed cells we exclude the requirement of Stat3 
for Smad2/3 nuclear translocation. Stat3 seems to have an impact on the expression 
of Smad2/3, especially upon treatment with TGF-β1, but also in untreated cells. The 
question remains, whether TGF-β1 directly forces Stat3 to activate the transcription 
of Smad2 or Smad3 or if there exists a feed-back loop that allows Stat3 to modulate 
transcription only in the case of reduced Smad levels or possibly after sustained 
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TGF-β1 signalling. Since Smads are not among the known Stat3 transcriptional 
targets it is unclear how it influences the Smad level. It is possible, that Stat3 affects 
a transcriptional mediator required for Smad-expression.  
Besides Smad signalling, TGF-β1 can also activate the MAP kinase pathway (112). 
Since there is evidence that Stat3 can be serine phosphorylated by MAP kinases  the 
finding that Stat3 is required for the execution of TGF-β1-induced effects could be 
rooted in this non-canonical signalling of TGF-β1 (67). Further, TGF-β-activated 
kinase 1 (TAK1) binds to Stat3 and triggers Ser727 phosphorylation (55). Serine 
phosphorylation can entail different effects, i.e. it can enhance or repress 
transcriptional activity (67). Since the binding of Stat1 to CBP/p300 was decreased 
upon loss of serine727 phoshphorylation, also Stat3 could require Ser727 
phosphorylation to bind CBP/p300, form complexes with Smad and modulate TGF-β-
Smad-mediated transcription (162). 
By focusing on Smad2/3 distribution in cell layers, we found that expression and 
translocation of Smad2/3 was stronger if not exclusively at the periphery of cell 
collections. This observation fits together with findings that migration and invasion of 
tumor cells can be enhanced by TGF-β1 treatment (137). Furthermore, at the 
invading edges of carcinomas TGF-β1-signalling was reported to be changed to the 
Smad2/3 linker phosphorylated isoform which was found to be more invasive and 
proliferative (130). Therefore, not only the change of phosphorylation sites but also 
the amount of expressed Smad2/3 contributes to the increase of malignancy and 
mobility of cells at the leading edges of tumors. In further experiments, the 
phosphoisotype of the expressed Smad2/3 should be investigated. Since the linker-
phosphorylated Smad3 isoform (pSmad3L) was associated with enhanced 
proliferative and invasive potential, we would expect to find mainly this isotype at the 
cell layer borders (123).  
The levels of Smad2/3 in wild type cells are enhanced upon TGF-β1 treatment. Thus, 
we assume that TGF-β1 enhances Smad2/3 expression. Even without Stat3 there 
was some Smad2/3 detected in TGF-β1-treated cells, but clearly less (Fig. 14, 15, 
lower panels). An expression analysis of Stat3 in MIM-stat3Δhc-wt-stat3 and MIM-R-
stat3Δhc-wt-Stat3 cells by Western blot analysis was performed before the 
experiments. Since Stat3 is expressed in both cell lines, the question arises where its 
different influence and capacity to rescue the phenotype upon reintroduction is based 
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on. One consideration would be that Ras-transformed cells are less sensitive to any 
influences at all and more autonomous in their growth due to their transformation (1).  
Furthermore, the crosstalk with the MAK kinase pathway could account for enhanced 
TGF-β1 tolerance of Ras-transformed cells. On the one hand, the activation of 
Erk/MAP kinase pathway by Ras can result in the inhibition of TGF- β1-induced 
growth arrest but on the other, Ras and TGF- β1 can act synergistically, since MAP 
kinase signalling is a non-canonical TGF- β signalling pathway (106, 121). So, since 
Ras and TGF-β1 converge in the activation of the same pathway, the constitutively 
active Ras could render the cells insensitive to treatment with TGF-β1.  
One pathway of inducing proliferation arrest upon TGF-β1 is the Smad-mediated 
release of c-myc from the promoters of the cyclin-dependent kinase (CDK) inhibitors 
p21WAF1 and p15Ink4B (113). Since c-myc is a prominent transcriptional target of Stat3 
we gave consideration into the possibility that this could be the crucial point of 
interference (66). The lack of Stat3 could entail a smaller amount of available c-myc, 
and thus the repression of the CDK inhibitors would be less. Consequently, we 
should observe diminished cell proliferation in Stat3-lacking cells. Since this was not 
the case, we exclude the role of Stat3 as transcription factor inducing the expression 
of c-myc as crucial for TGF-β1-induced anti-proliferative effects. 
There are a few transcriptional targets known to be shared by Stat3 and TGF-β 
Smad2/3. Among them are VEGF, MMP-2 and MMP-9 (66, 136, 137). These 
proteins affect the tumor-microenvironment. Smad2/3 binds to Smad-binding 
elements on DNA and Stat3 can induce the expression of genes containing SBEs in 
their promoters (111, 163). Possibly, there are other targets that need the concerted 
action of Stat3 and Smad2/3 to forward TGF-β-induced anti-proliferative and 
apoptotic effects. Bone morphogenic protein, which is a protein of the TGF- β family, 
activates Smad-Stat3 complexes to induce gene expression of ID1 (164). Smad1 and 
Stat3 both bind to the p300 cofactor to induce the expression of a set of genes 
leading to astrocyte differentiation (165). Smad1/p300 complex binds to Stat1/3 on 
glial-specific promoters (166). These findings strongly support this hypothesis. 
Since the induction of apoptosis upon TGF-β was reported to be mediated via death-
associated protein kinase (DAPK) in a hepatoma cell line, and via signalling factor 
GADD45b in hepatocytes, it would be of interest if the activity of these proteins is 
affected by the lack of Stat3 in our model system (108).  
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Src activation is a Smad-independent pathway of TGF-β signal transduction (106). 
Stat3 is a target of src tyrosine kinase, and this could be the reason why the lack of 
Stat3 impairs the anti-mitogenic effects of TGF-β (15). To prove this assumption it 
would be necessary to show that the proliferation-inhibitory and apoptotic effects of 
TGF-β rely largely on scr kinase activity. This could be achieved if elevated levels of 
activated src were found upon TGF-β treatment and if the outcome of cell fate was 
changed in src kinase inactive of missing conditions.  
In summary, we conclude that Stat3 is necessary for TGF-β1-induced transcription of 
Smad2/3 but not its nuclear translocation, and the lack of Stat3 impairs TGF-β1-
mediated negative effects on survival and proliferation in untransformed and Ras-
transformed hepatocytes. However, the inhibition of Stat3 would be harmful for 
patients since the tumor-suppressive effect of TGF-β1 at early stages of tumor 
development gets blunted.  
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7. Abbreviations 
APS, ammonium persulfate 
ARF, p14ARF and p19ARF 
BAD, Bcl-2 associated death  
BMP, bone morphogenic protein 
BSA, bovine serum albumin 
ca, constitutively active 
CBP, Creb binding protein 
CDK, cyclin-dependent kinase 
DAPK, death associated protein kinase 
DMEM, Dulbecco's Modified Eagle's Medium 
DNMT, DNA-methyltransferase 
Erk, extracellular signal-regulated kinase 
FCS, fetal calf serum 
HCC, human hepatocellular carcinoma 
HDM2, human double minute 2 
HGF, hepatocyte growth factor 
HIF1α, hypoxia-induced factor 1-α 
I-Smads, inhibitory Smads 
ID, inhibitor of differentiation 
IFN, interferon 
IGF-II, insulin-like growth factor 
IL, interleukin 
Jak, Janus kinase 
MAPK, mitogen-activated protein kinase 
MDM2, murine double minute 2 
MEF, mouse embryonic fibroblasts 
MH, Mad homology domain 
MMP, matrix metalloprotease 
mTOR, mammalian target of rapamycin 
NMP, nucleophosmin 
PAA, polyacrylic acid 
Pan-jak, Jak1 – 3 and Tyk2 
PBS, phosphate buffered saline 
PI3K, phosphatidylinositol-3-kinase 
Plc, Plc/prf/5 
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Plc-p14, Plc/prf/5-p14ARF 
pSmad3L, linker phosphorylated Smad3 
PTEN, phosphatase and tensin homologue deleted on chromosome ten 
PTPRT, protein tyrosine phosphatase receptor-T 
pY-Stat3, tyrosine 705 phosphorylated Stat3 
R-Smads, receptor-associated Smads  
Raf, Ras-acitvated factor 
RIPA buffer, Radioimmunoprecipitation assay buffer 
RPMI, RPMI-1640 cell culture medium 
RT, room temperature 
SBE, Smad binding element 
SCID, severe combined immunodeficiency 
SDS, sodium-dodecyl-sulfate  
Ser, serine 
sh, small hairpin 
SH2, Src homology 2 
shc, small hairpin control 
SHIP, SH2 domain-containing inositol 5'phosphatases  
SHP-1, Src homology 2 domain-containing protein tyrosine phosphatase 1 
si, small interfering 
SOCS, suppressor of cytokine signalling 
Stat3, Signal transducer and activator of transcription 3 
TAK1, TGF-β-activated-kinase 1 
TBST, Tris-buffered saline-0,1% Tween  
TEMED, tetramethylethylenediamine  
TGF-ß1, transforming growth factor ß1 
TGF-α, transforming-frowth factor-α  
Tyk, Tyrosine kinase 
Tyr, tyrosine 
TβR, TGF-β receptor type 
U-Stat, unphosphorylated Stat 
wt, wild type 
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